

Isolation of Highly Infectious and Pure Adeno-Associated Virus Type 2 Vectors with a Single-Step Gravity-Flow Column

ALBERTO AURICCHIO,* MARKUS HILDINGER,* ERIN O'CONNOR, GUANG-PING GAO,
and JAMES M. WILSON

ABSTRACT

One of the most promising gene transfer vectors in human clinical trials is AAV2. The quality of the vector preparations is a key element in obtaining reliable and reproducible data in preclinical studies. However, established protocols either result in impure, low infectious virus (CsCl₂ gradient centrifugation) or demand a high level of manual and technical skills (CsCl₂ gradient centrifugation, iodixanol/heparin or HPLC purification). In this study, we present an easy-to-do single-step column purification (SSCP) of AAV2 by gravity flow based on its affinity to heparin, without ultracentrifugation. Various vector preparations generated by our method reproducibly showed high titers, infectivity, and purity. *In vivo*, our single-step column-purified AAV2 vectors mediate significantly higher transduction efficiency compared with conventional protocols. Investigators still unsatisfied with previously published techniques or new to the field of AAV production may find in our method an interesting alternative.

OVERVIEW SUMMARY

We developed a single-step gravity-flow column purification method for AAV2 based on its affinity for heparin. Briefly, after production of viral particles in the packaging cell line, using triple transfection, the cell lysate containing the vector is loaded on a preequilibrated heparin column. The heparin-virus complex is then washed and AAV2 is finally eluted by a simple buffer exchange to high salt. We demonstrate that recombinant AAV2 purified by this simple and scalable method is reproducibly highly infectious *in vitro* and *in vivo*. In addition, its purity is comparable to vector obtained using protocols requiring more complex skills and equipment.

INTRODUCTION

RECOMBINANT ADENO-ASSOCIATED VIRUS TYPE 2 (AAV2) holds much promise for human gene therapy (Rabinowitz and Samulski, 1998; Bennett *et al.*, 1999; Kay *et al.*, 2000). The quality of AAV2 vector preparations is a key element in obtaining reliable and reproducible data (Summerford and

Samulski, 1999). Purification of AAV based on CsCl₂ gradients was the first method described and still is the most commonly used (Toolan, 1968). However, this technique yields preparations with a considerable amount of contaminating non-viral proteins and a high ratio of genome copies versus infectious units. These factors may also vary from lot to lot and complicate the comparison of results from independent experiments. Several improved methods have been published (Grimm *et al.*, 1998; Clark *et al.*, 1999; Zolotukhin *et al.*, 1999; Gao *et al.*, 2000). One is based on a combination of ultracentrifugation in iodixanol (instead of CsCl₂) and subsequent affinity purification using a heparin column; two others rely on high-performance liquid chromatography (HPLC). Whereas the method published by Gao *et al.* uses a combination of a POROS HE and a POROS 50 PI column, Clark *et al.* describe an HPLC purification based on a POROS HE1/M column. Last, but not least, purification of AAV2 by use of a monoclonal antibody has been reported (Anderson *et al.*, 2000). All these protocols result in AAV2 preparations that are purer and more infectious than those obtained with the conventional CsCl₂ protocol.

However, these improved methods still require technical skills and special equipment (ultracentrifuge or HPLC machine), which complicates the purification of larger production

Wistar Institute, Philadelphia, PA 19104.

*Both authors contributed equally to this work.

lots. A protocol would be desirable that combines the ease of plasmid column purification with the purity and infectivity of HPLC-purified virus.

In this study, we describe a single-step gravity-flow column purification protocol for AAV2, based on its affinity for heparin. This technique does not require expensive, special equipment or advanced skills, is highly reproducible, and comes close to HPLC-purified virus with respect to purity and infectivity. Briefly, the crude lysate containing the recombinant vector is directly applied to a preequilibrated heparin column. On binding of the virus to the matrix and after two washes, the vector is eluted by a change in buffer and concentrated.

This simple and fast protocol represents an interesting alternative to other published, improved AAV production methods.

MATERIALS AND METHODS

Plasmid constructs

The AAV2 packaging plasmid p600 trans and the Ad helper plasmid p Δ F6 have been described (Zhang *et al.*, 2000). The sequences of the AAV2 *cis* vectors can be sent electronically on request. Plasmid DNA was purified with an EndoFree Giga Plasmid preparation kit (Qiagen, Hilden, Germany).

Vector production

For one AAV2 vector preparation, fifty 15-cm dishes of subconfluent, low-passage 293 cells (American Type Culture Collection [ATCC], Manassas, VA) were transfected by calcium phosphate (Clontech, Palo Alto, CA) with 2 mg of plasmid DNA (p600 trans, p Δ F6 and the AAV2 *cis* vector). Medium was changed the following day, and cells were harvested 3 days after transfection.

Vector purification

CsCl₂ and iodixanol/heparin purifications were performed as described (Zolotukhin *et al.*, 1999; Zhang *et al.*, 2000). For the single-step column purification (SSCP) protocol, cells contained in one 15-cm dish were resuspended in 2.5 ml of Dulbecco's modified Eagle's medium (DMEM) (Cellgro; Mediatech, 10-013-CM [Herndon, VA]), frozen, and thawed two times and incubated with 0.1 mg each of DNase I and RNase A (Roche Biochemicals, Mannheim, Germany) for 30 min at 37°C. After 15 min of centrifugation at 3000 rpm in a Sorvall RT6000D centrifuge at 4°C, the supernatant was transferred into a new tube, incubated with 0.5% (final concentration) deoxycholic acid (Sigma D6750, lot 19H0696; Sigma, St. Louis, MO) for 30 min at 37°C, and sequentially filtered through a 5- μ m pore size filter (Millipore, SLSV R25 LS [Bedford, MA]) and a 0.8- μ m pore size filter (Millipore, SLAA O25 LS). The cleared crude lysate was then applied on a heparin column prepared in the following way: 8 ml of a heparin-agarose suspension (Sigma H6508) was pipetted into a 2.5-cm-diameter glass column (Sigma C4669) equipped with a Luer Lock (Sigma S7396). After the agarose suspension solution flowed through, a filtration membrane (Sigma S7271) was placed on top of the agarose bedding. The matrix was afterward equilibrated with 25 ml of phosphate-buffered saline (PBS), pH 7.4 (Life Technologies, Gaithersburg, MD). After closing the Luer Lock, the filtered crude lysate was applied to the column. The lock was

then opened so that the flow speed was 1 drop/sec. After all the lysate went through the column (which requires several loadings), the matrix was washed twice with 25 ml of PBS, pH 7.4, plus 0.1 M NaCl (i.e., PBS with a final concentration of 0.254 M NaCl). The virus was then eluted with 15 ml of PBS, pH 7.4, plus 0.4 M NaCl. The eluate was concentrated to about 1 ml with a Millipore Biomax-100K NMWL filter device (UFV2BHK40) by centrifugation. To adjust the NaCl concentration to physiological levels, the filter device was refilled with PBS, pH 7.4, and the virus was concentrated to 1 ml again. After removal of the virus-containing solution, the membrane of the filter device was washed three times with 100 μ l of PBS, pH 7.4, which was added to the main part of the recombinant AAV2.

It is possible to reuse each of the affinity column components. The glass column, Luer Lock, and sample diffusion disk have been sterilized and reutilized by the authors. Theoretically the resin can be reused as well after a thorough wash (i.e., 1 M NaCl in PBS). Nevertheless, because of the relatively low cost of heparin and the possibility of a residual cross-contamination, we discourage the recycling of matrix.

For our protocol, we consider critical four steps: (1) two (instead of three) rounds of freeze and thaw (the third round decreases the yield of infectious virus by $27 \pm 3.2\%$; our unpublished data); (2) the removal of cellular debris before adding deoxycholic acid; (3) addition of deoxycholic acid to the lysate (otherwise the virus does not bind to heparin); and (4) the use of appropriate PBS.

Vector characterization

Genome copies were determined by Real-Time PCR, using TaqMan (Perkin-Elmer Biosystems, Foster City, CA) (Gao *et al.*, 2000). Transducing units were assessed by limiting dilution of virus on 84/31 cells (Gao *et al.*, 2000). The number of green fluorescent protein (GFP)-positive cells was determined by fluorescence-activated cell sorting (FACS), the number of LacZ-positive cells by histochemical 5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside (X-Gal) staining.

Purity of viral preparations was assessed by loading 10¹⁰ genome copies on sodium dodecyl sulfate (SDS)-polyacrylamide gel (4–12% acrylamide gradient gel; Novex/Invitrogen, Carlsbad, CA) run under reducing conditions. Protein was detected by Coomassie staining.

For analysis of transduction efficiency *in vivo*, the tibialis anterior muscles of immunocompetent C57BL/6 mice (three animals per group) were injected with 10⁶ to 10⁷ genome copies of AAV2 CMV *lacZ* (Fisher *et al.*, 1997), purified either by CsCl₂ or SSCP. Muscles were harvested 28 days after injection and either lysed for subsequent β -galactosidase (β -Gal) enzyme-linked immunosorbent assay (ELISA) analysis (Roche Biochemicals) or frozen, cut, and stained for LacZ expression (Fisher *et al.*, 1997).

RESULTS

Previous reports have revealed that CsCl₂-purified AAV2 vectors show a high ratio of genomic copies to transducing units (Clark *et al.*, 1999; Zolotukhin *et al.*, 1999). To test whether this is due to the CsCl₂ itself, we incubated in two independent ex-




FIG. 1. Stability of AAV2 in CsCl₂. A total of 10^{10} genomic particles of AAV2 CMV *lacZ* was incubated in either CsCl₂ (1.4 g/cm³; for 24, 48, or 72 hr) or PBS (for 72 hr, designated 0 [0 hr in CsCl₂]) at 4°C. 293 cells were then infected at an MOI of 1 and stained after 3 days for gene expression. The experiment was performed twice, each time in duplicate. *Top*: The relative infectivity compared with virus in PBS over time. *Bottom*: LacZ-positive cells transduced with virus incubated for 0, 24, 48, and 72 hr in CsCl₂.

periments (each performed in duplicate) 10^{10} genome copies of AAV2 CMV *lacZ* in either CsCl₂ (1.4 g/cm³) or in the original buffer (PBS) for up to 72 hr at 4°C. 293 cells were then infected at a multiplicity of infection (MOI) of 1 and stained after 3 days for gene expression (Fig. 1). The number of LacZ-positive cells decreased by a factor of 2 each day the virus was incubated in CsCl₂. After 72 hr (corresponding to the time it takes to perform two rounds of CsCl₂ ultracentrifugation), only about 13% of the original virus was still infectious. We, therefore, developed a protocol that does not rely on CsCl₂ gradient centrifugation, but

on the ability of AAV2 to bind to heparin (Summerford and Samulski, 1998), and compared it with established protocols. We focused our comparison on the most widely used CsCl₂ centrifugation and iodixanol/heparin purification protocol (Zolotukhin *et al.*, 1999), as the necessary reagents are commonly available and no special equipment (HPLC machine) is required.

A preparation of 300 15-cm dishes of 293 cells were triple-transfected with an AAV2 CMV eGFP *cis* plasmid, the packaging plasmid, and the Ad helper plasmid. Cells were harvested 3 days later, and two sets of 50 plates were independently pu-

TABLE 1. COMPARISON OF CsCl₂-, IODIXANOL-, AND SSCP-PURIFIED VECTORS: GENOME COPIES AND TRANSDUCING UNITS

Method	GC	TU	Ratio GC/TU	Average GC yield	Average TU yield	Average GC/TU
CsCl ₂ 1	8.0×10^{12}	7.2×10^{10}	111			
CsCl ₂ 2	6.6×10^{12}	1.8×10^{11}	37	7.3×10^{12}	3.9×10^{10}	74
Iodixanol 1	1.35×10^{12}	3.4×10^{10}	40	1.8×10^{12}	1.1×10^{11}	35
Iodixanol 2	2.2×10^{12}	7.5×10^{10}	30			
SSCP 1	6.24×10^{12}	6.0×10^{11}	10.4	5.7×10^{12}	5.5×10^{11}	8.4
SSCP 2	5.2×10^{12}	8.3×10^{11}	6.3			

Abbreviations: GC, genome copies; TU, transducing units.

TABLE 2. REPRODUCIBILITY OF VECTOR PREPARATIONS BY SSCP

Vector	Size (kb)	Genome copies	Transducing units	Ratio
AAV2 CMV <i>lacZ</i>	4.9	1.8×10^{12}	1.5×10^{10}	120
		2.7×10^{12}	2.1×10^{10}	144
		4.5×10^{12}	5.6×10^{10}	81
		1.4×10^{12}	1.1×10^{10}	129
AAV2 CMV eGFP	2.7	6.0×10^{12}	6.0×10^{11}	10
		3.6×10^{12}	3.1×10^{11}	12
		1.4×10^{13}	1.3×10^{12}	11
		1.1×10^{13}	1.4×10^{12}	8
AAV2 TBG <i>lacZ</i>	5.1	4.8×10^{12}	ND	ND
AAV2 TBG insulin	2.4	3.7×10^{12}	ND	ND
AAV2 TBG OTC	3.1	1.4×10^{12}	ND	ND

Abbreviations: ND, not determined; TBG, thyroxine-binding globulin promoter; OTC, ornithine transcarbamoylase.

rified according to each protocol (Table 1). Similar genome copy yields, higher than with the iodixanol protocol, were obtained with our method and the CsCl₂ method. However, the ratio of genome copies to transducing units was about 10-fold higher with the CsCl₂ technique, meaning that about 10 times more genome copies are required to infect the same number of cells. A similar estimate of infectivity was obtained by infectious center assay (ICA [Gao *et al.*, 2000]; data not shown). The reported infectivity of HPLC preparations (Clark *et al.*, 1999; Gao *et al.*, 2000) is equivalent to SSCP-generated vectors.

To test the reproducibility of our method, we generated AAV2 virus preparations, each from 50 triple-transfected 15-cm dishes, with various expression cassettes and genome sizes (Table 2). High yields (genome copies and transducing units) were obtained reproducibly, independent of the *cis* vector design. In these experiments up to 1.4×10^{13} particles of AAV2 could be purified and concentrated using 8 ml of agarose–heparin suspension. An upper limit of virus binding to heparin could not be

determined with the amount of virus used in our experiments so far. In addition, the purity of some preparations was examined by SDS-polyacrylamide gel electrophoresis (PAGE) (Fig. 2): 10^{10} genome copies were loaded per lane along with the same amount of CsCl₂-purified particles. The most abundant proteins in all the SSCP lots were VP1, VP2, and VP3. In addition, three minor bands, identical in each lane, could also be detected. Altogether, the purity of SSCP-produced vectors is similar to that reported for iodixanol/heparin (Zolotukhin *et al.*, 1999) and HPLC (Clark *et al.*, 1999; Gao *et al.*, 2000).

To confirm *in vivo* the higher infectivity of the SSCP-purified vectors observed in cell culture, various vector doses of both CsCl₂- and SSCP-generated preparations were administered to the muscle of C57BL/6 mice (Fig. 3A). Twenty-eight days after injection, the muscles were harvested, and the relative β -galactosidase expression was assessed by ELISA. With increasing viral dose, up to 5-fold higher, gene expression could be detected with the SSCP-prepared virus compared with




FIG. 2. Comparison of CsCl₂- versus SSCP-purified vectors: purity. A total of 10^{10} genome copies was loaded and separated on a reducing SDS-polyacrylamide gel (4–12% acrylamide gradient gel). Protein was detected by Coomassie staining. Lane 1 shows recombinant AAV2 CMV eGFP virus purified with CsCl; lanes 2 to 5 were loaded with four different preparations of the same vector purified by SSCP.




FIG. 3. Comparison of CsCl_2 - versus SSCP-purified vectors: transduction *in vivo*. The tibialis anterior muscles of immunocompetent C57BL/6 mice were injected, harvested, and analyzed as described in Materials and Methods. (A) β -Galactosidase expression relative to transduction of muscle tissue with 10^6 – 10^7 genome copies of CsCl_2 -purified AAV2 CMV *lacZ* (mean value of three animals per group). (* β -Galactosidase expression with 10^6 genomic particles of CsCl_2 -purified virus set to 1.) (B) X-Gal staining of transduced muscles.

CsCl_2 -purified virus. Only on administration of virus produced by our technique could cells be visualized by the less sensitive X-Gal staining (Fig. 3B).

DISCUSSION

Purification of AAV2 on the basis of its affinity for heparin (Summerford and Samulski, 1998) has arisen as an alternative to CsCl_2 ultracentrifugation (Table 3). In this report, we describe an improvement on existing affinity purification protocols (Tamayose *et al.*, 1996; Grimm *et al.*, 1998; Clark *et al.*, 1999; Zolotukhin *et al.*, 1999; Anderson *et al.*, 2000; Gao *et al.*, 2000) in terms of simplicity. Briefly, the virus producer cells are lysed

in DMEM, and the crude lysate is directly applied to a pre-equilibrated column, packaged with commercially available heparin–agarose. On binding of the virus in the presence of 0.5% deoxycholic acid, the matrix is washed with PBS plus 0.1 M NaCl and the virus is then eluted with PBS plus 0.4 M NaCl. Whereas in the single-column HPLC protocol virus is eluted with a linear NaCl gradient (Clark *et al.*, 1999), we use a simple buffer exchange to high salt. Our protocol does not require more technical skills or equipment (in particular, no ultracentrifuge or HPLC equipment) than a commercially available column purification of plasmid DNA. Virus can be purified within one afternoon, reducing the total production time by at least 2 days compared with the still most commonly used CsCl_2 purification method. In addition, affinity purification of AAV2 al-

TABLE 3. SUMMARY

	<i>CsCl</i> ₂ protocol	Iodixanol/heparin protocol	HPLC protocol (heparin)	SSCP protocol
Total time:	6 days	4 days	4 days	4 days
Gradient centrifugation:	Yes	Yes	No	No
Special equipment:	Ultracentrifuge, refractometer	Ultracentrifuge	HPLC machine	No
Cost for purification in US\$:	185	ND	ND	120
Ratio genome copies/Transducing units:	~75	~35	~10	~10
Purity ^a :	4	1–2	1	1–2
Difficulty in learning the technique ^b :	3	2–3	4	1–2

Abbreviation: ND, not determined.

^aGrade for purity: 1, low level of cellular contaminants as detected by SDS-PAGE; 4, high level of cellular contaminants as detected by SDS-PAGE.

^bGrades for difficulty in learning the technique: 1, easy; 4, difficult.

lows the recovery of virus without the major cellular contaminants present when a physical separation method such as CsCl₂ density centrifugation is used. More importantly, as AAV2 is unstable in CsCl₂, our method yields highly infectious virus with ratios of genome copies to transducing units of up to 6. Similar results are reported for HPLC and iodixanol/heparin (Clark *et al.*, 1999; Zolotukhin *et al.*, 1999; Gao *et al.*, 2000).

In conclusion, the single-step column purification of AAV2 described here should prove a valuable tool for investigators either struggling with existing protocols or seeking a convenient way to improve the potency of their AAV2 preparations.

ACKNOWLEDGMENTS

We appreciate the support of the animal care facility of the Institute for Human Gene Therapy. This work was supported by grants from the NIH (P30 DK47757 and U42 RR11151), the Cystic Fibrosis Foundation, the Juvenile Diabetes Foundation, and Genovo, a biotechnology company that Dr. Wilson founded and holds equity in. A.A. was supported by a grant from Telethon-Italia (371-B).

REFERENCES

- ANDERSON, R., MACDONALD, I., CORBETT, T., WHITEWAY, A., and PRENTICE, H. (2000). A method for the preparation of highly purified adeno-associated virus using affinity column chromatography, protease digestion and solvent extraction. *J. Virol. Methods* **85**, 23–34.
- BENNETT, J., MAGUIRE, A.M., CIDECIYAN, A.V., SCHNELL, M., GLOVER, E., ANAND, V., ALEMAN, T.S., CHIRMULE, N., GUPTA, A.R., HUANG, Y., GAO, G.-P., NYBERG, W.C., TAZELAAR, J., HUGHES, J.V., WILSON, J.M., and JACOBSON, S.G. (1999). Stable transgene expression in rod photoreceptors after recombinant adeno-associated virus-mediated gene transfer to monkey retina. *Proc. Natl. Sci. Acad. U.S.A.* **96**, 9920–9925.
- CLARK, K., LIU, X., McGRATH, J., and JOHNSON, P. (1999). Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. *Hum. Gene Ther.* **10**, 1031–1039.
- FISHER, K.J., JOOSS, K., ALSTON, J., YANG, Y., HAECKER, S.E., HIGH, K., PATHAK, R., RAPER, S.E., and WILSON, J.M. (1997). Recombinant adeno-associated virus for muscle directed gene therapy. *Nat. Med.* **3**, 306–312.
- GAO, G., QU, Q., BURNHAM, M., HUANG, J., CHIRMULE, N., JOSHI, B., YU, Q., MARSH, J., CONCEICAO, C., and WILSON, J. (2000). Purification of recombinant adeno-associated virus vectors by column chromatography and its performance *in vivo*. *Hum. Gene Ther.* **11**, 2079–2091.
- GRIMM, D., KERN, A., RITTNER, K., and KLEINSCHMIDT, J.A. (1998). Novel tools for production and purification of recombinant adeno-associated virus vectors. *Hum. Gene Ther.* **9**, 2745–2760.
- KAY, M., MANNO, C., RAGNI, M., LARSON, P., COUTO, L., McCLELLAND, A., GLADER, B., CHEW, A., TAI, S., HERZOG, R., ARRUDA, V., JOHNSON, F., SCALLAN, C., SKARSGARD, E., FLAKE, A., and HIGH, K. (2000). Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. *Nat. Genet.* **24**, 257–261.
- RABINOWITZ, J., and SAMULSKI, J. (1998). Adeno-associated virus expression systems for gene transfer. *Curr. Opin. Biotechnol.* **9**, 470–475.
- SUMMERFORD, C., and SAMULSKI, R.J. (1998). Membrane-associated heparin sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. *J. Virol.* **72**, 1438–1445.
- SUMMERFORD, C., and SAMULSKI, R. (1999). Viral receptors and vector purification: New approaches for generating clinical-grade reagents. *Nat. Med.* **5**, 587–588.
- TAMAYOSE, K., HIRAI, Y., and SHIMADA, T. (1996). A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. *Hum. Gene Ther.* **7**, 507–513.
- TOOLAN, H. (1968). The picodna viruses. H, RV, and AAV. *Int. Rev. Exp. Pathol.* **6**, 135–180.
- ZHANG, Y., CHIRMULE, N., GAO, G., and WILSON, J. (2000). CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors *in vivo*: Role of immature dendritic cells. *J. Virol.* **74**, 8003–8010.
- ZOLOTUKHIN, S., BYRNE, B., MASON, E., ZOLOTUKHIN, I., POTTER, M., CHESNUT, K., SUMMERFORD, C., SAMULSKI, R., and MUZYCZKA, N. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. *Gene Ther.* **6**, 973–985.

Address reprint requests to:

Dr. James M. Wilson

204 Wistar Institute

3601 Spruce Street

Philadelphia, PA 19104-4268

E-mail: wilsonjm@mail.med.upenn.edu

Received for publication September 15, 2000; accepted after revision October 26, 2000.

This article has been cited by:

1. Giuliano De Carluccio, Virginia Fusco, Diego di Bernardo. 2024. Engineering a synthetic gene circuit for high-performance inducible expression in mammalian systems. *Nature Communications* 15:1. . [\[Crossref\]](#)
2. Julio Huato Hernandez, Kurt Boenning, Aydin Kavara, Mark Schofield. 2024. Membrane chromatography for AAV full capsid enrichment: Process development to scale up. *Journal of Chromatography B* 1244, 124258. [\[Crossref\]](#)
3. Federica Esposito, Fabio Dell'Aquila, Manuel Rhiel, Stefano Auricchio, Kay Ole Chmielewski, Geoffroy Andrieux, Rita Ferla, Paula Sureda Horrach, Arjun Padmanabhan, Roberto Di Cunto, Simone Notaro, Manel Llado Santeularia, Melanie Boerries, Margherita Dell'Anno, Edoardo Nusco, Agnese Padula, Sofia Nutarelli, Tatjana I. Cornu, Nicolina Cristina Sorrentino, Pasquale Piccolo, Ivana Trapani, Toni Cathomen, Alberto Auricchio. 2024. Safe and effective liver-directed AAV-mediated homology-independent targeted integration in mouse models of inherited diseases. *Cell Reports Medicine* 5:7, 101619. [\[Crossref\]](#)
4. Mikako Wada, Naoya Uchida, Guillermo Posadas-Herrera, Hiromi Hayashita-Kinoh, Yuji Tsunekawa, Yukihiko Hirai, Takashi Okada. 2023. Large-scale purification of functional AAV particles packaging the full genome using short-term ultracentrifugation with a zonal rotor. *Gene Therapy* 30:7-8, 641-648. [\[Crossref\]](#)
5. Iolanda Boffa, Elena Polishchuk, Lucia De Stefano, Fabio Dell'Aquila, Edoardo Nusco, Elena Marrocco, Matteo Audano, Silvia Pedretti, Marianna Caterino, Ilaria Bellezza, Margherita Ruoppolo, Nico Mitro, Barbara Cellini, Alberto Auricchio, Nicola Brunetti-Pierri. 2023. Liver-directed gene therapy for ornithine aminotransferase deficiency. *EMBO Molecular Medicine* 15:4. . [\[Crossref\]](#)
6. Aoife Mairéad Kearney. Chromatographic Purification of Viral Vectors for Gene Therapy Applications 51-60. [\[Crossref\]](#)
7. Patrizia Tornabene, Rita Ferla, Manel Llado-Santaularia, Miriam Centrulo, Margherita Dell'Anno, Federica Esposito, Elena Marrocco, Emanuela Pone, Renato Minopoli, Carolina Iodice, Edoardo Nusco, Settimio Rossi, Hristiana Lyubenova, Anna Manfredi, Lucio Di Filippo, Antonella Iuliano, Annalaura Torella, Giulio Piluso, Francesco Musacchia, Enrico Maria Surace, Davide Cacchiarelli, Vincenzo Nigro, Alberto Auricchio. 2022. Therapeutic homology-independent targeted integration in retina and liver. *Nature Communications* 13:1. . [\[Crossref\]](#)
8. Sabrina Carrella, Martina Di Guida, Simona Brillante, Davide Piccolo, Ludovica Ciampi, Irene Guadagnino, Jorge Garcia Piqueras, Mariateresa Pizzo, Elena Marrocco, Marta Molinari, Georgios Petrogiannakis, Sara Barbato, Yulia Ezhova, Alberto Auricchio, Brunella Franco, Elvira De Leonibus, Enrico Maria Surace, Alessia Indrieri, Sandro Banfi. 2022. miR -181a/b downregulation: a mutation-independent therapeutic approach for inherited retinal diseases. *EMBO Molecular Medicine* 14:11. . [\[Crossref\]](#)
9. Lyubava Belova, Konstantin Kochergin-Nikitsky, Anastasia Erofeeva, Alexander Lavrov, Svetlana Smirnikhina. 2022. Approaches to purification and concentration of rAAV vectors for gene therapy. *BioEssays* 44:6. . [\[Crossref\]](#)
10. Pranav R.H. Joshi, Alice Bernier, Pablo D. Moço, Joseph Schrag, Parminder S. Chahal, Amine Kamen. 2021. Development of a scalable and robust AEX method for enriched rAAV preparations in genome-containing VCs of serotypes 5, 6, 8, and 9. *Molecular Therapy - Methods & Clinical Development* 21, 341-356. [\[Crossref\]](#)
11. Ying Kai Chan, Sean K. Wang, Colin J. Chu, David A. Copland, Alexander J. Letizia, Helena Costa Verdera, Jessica J. Chiang, Meher Sethi, May K. Wang, William J. Neidermyer, Yingleong Chan, Elaine T. Lim, Amanda R. Graveline, Melinda Sanchez, Ryan F. Boyd, Thomas S. Vihtelic, Rolando Gian Carlo O. Inciong, Jared M. Slain, Priscilla J. Alphonse, Yunlu Xue, Lindsey R. Robinson-McCarthy, Jenny M. Tam, Maha H. Jabbar, Bhuvananda Sahu, Janelle F. Adeniran, Manish Muhuri, Phillip W. L. Tai, Jun Xie, Tyler B. Krause, Andyna Vernet, Matthew Pezone, Ru Xiao, Tina Liu, Wei Wang, Henry J. Kaplan,

- Guangping Gao, Andrew D. Dick, Federico Mingozzi, Maureen A. McCall, Constance L. Cepko, George M. Church. 2021. Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. *Science Translational Medicine* 13:580. . [[Crossref](#)]
12. Susanna Croci, Miriam Lucia Carriero, Katia Capitani, Sergio Daga, Francesco Donati, Elisa Frullanti, Vittoria Lamacchia, Rossella Tita, Annarita Giliberti, Floriana Valentino, Elisa Benetti, Annalisa Ciabattini, Simone Furini, Caterina Lo Rizzo, Anna Maria Pinto, Silvestro Giovanni Conticello, Alessandra Renieri, Ilaria Meloni. 2020. High rate of HDR in gene editing of p.(Thr158Met) MECP2 mutational hotspot. *European Journal of Human Genetics* 28:9, 1231-1242. [[Crossref](#)]
 13. Matilde Negrini, Gang Wang, Andreas Heuer, Tomas Björklund, Marcus Davidsson. 2020. AAV Production Everywhere: A Simple, Fast, and Reliable Protocol for In-house AAV Vector Production Based on Chloroform Extraction. *Current Protocols in Neuroscience* 93:1. . [[Crossref](#)]
 14. Alberto Auricchio, Miguel Sena-Esteves, Guangping Gao. 2020. Purification of Recombinant Adeno-Associated Virus 2 (rAAV2) by Heparin Column Affinity Chromatography. *Cold Spring Harbor Protocols* 2020:5, pdb.prot095620. [[Crossref](#)]
 15. Shubham Maurya, Bertin Mary, Giridhara R. Jayandharan. 2019. Rational Engineering and Preclinical Evaluation of Neddylation and SUMOylation Site Modified Adeno-Associated Virus Vectors in Murine Models of Hemophilia B and Leber Congenital Amaurosis. *Human Gene Therapy* 30:12, 1461-1476. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
 16. Yong Zeng, Haohua Qian, Zhijian Wu, Dario Marangoni, Paul A. Sieving, Ronald A. Bush. 2019. AAVrh-10 transduces outer retinal cells in rodents and rabbits following intravitreal administration. *Gene Therapy* 26:9, 386-398. [[Crossref](#)]
 17. Maddalena Andrea, Dell'Aquila Fabio, Giovannelli Pia, Tiberi Paola, Wanderlingh Luca Giorgio, Montefusco Sandro, Tornabene Patrizia, Iodice Carolina, Visconte Feliciano, Carissimo Annamaria, Medina Diego Luis, Castoria Gabriella, Auricchio Alberto. 2018. High-Throughput Screening Identifies Kinase Inhibitors That Increase Dual Adeno-Associated Viral Vector Transduction In Vitro and in Mouse Retina. *Human Gene Therapy* 29:8, 886-901. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
 18. Magalie Penaud-Budloo, Achille François, Nathalie Clément, Eduard Ayuso. 2018. Pharmacology of Recombinant Adeno-associated Virus Production. *Molecular Therapy - Methods & Clinical Development* 8, 166-180. [[Crossref](#)]
 19. Andrea Maddalena, Patrizia Tornabene, Paola Tiberi, Renato Minopoli, Anna Manfredi, Margherita Mutarelli, Sertimio Rossi, Francesca Simonelli, Jurgen K. Naggert, Davide Cacchiarelli, Alberto Auricchio. 2018. Triple Vectors Expand AAV Transfer Capacity in the Retina. *Molecular Therapy* 26:2, 524-541. [[Crossref](#)]
 20. Ivana Trapani. Dual AAV Vectors for Stargardt Disease 153-175. [[Crossref](#)]
 21. Rachel E. Kelemen, Sarah B. Erickson, Abhishek Chatterjee. Production and Chemoselective Modification of Adeno-Associated Virus Site-Specifically Incorporating an Unnatural Amino Acid Residue into Its Capsid 313-326. [[Crossref](#)]
 22. Jeffrey B. Mason, Brittney L. Gurda, Kurt D. Hankenson, Lindsey R. Harper, Cathy S. Carlson, James M. Wilson, Dean W. Richardson. 2017. Wnt10b and Dkk-1 gene therapy differentially influenced trabecular bone architecture, soft tissue integrity, and osteophytosis in a skeletally mature rat model of osteoarthritis. *Connective Tissue Research* 58:6, 542-552. [[Crossref](#)]
 23. Yumei Xiong, Kenneth Walker, Xiaoshan Min, Clarence Hale, Thanhvien Tran, Renee Komorowski, Jerry Yang, Jasmine Davda, Noi Nuanmanee, Dao Kemp, Xiaozhen Wang, Hantao Liu, Silke Miller, Ki Jeong Lee, Zhulun Wang, Murielle M. Véniant. 2017. Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys. *Science Translational Medicine* 9:412. . [[Crossref](#)]
 24. Misako Komatsu, Eriko Sugano, Hiroshi Tomita, Naotaka Fujii. 2017. A Chronically Implantable Bidirectional Neural Interface for Non-human Primates. *Frontiers in Neuroscience* 11. . [[Crossref](#)]

25. Tingting Zhou, Hong Zhu, Zhengxiao Fan, Fei Wang, Yang Chen, Hexing Liang, Zhongfei Yang, Lu Zhang, Longnian Lin, Yang Zhan, Zheng Wang, Hailan Hu. 2017. History of winning remodels thalamo-PFC circuit to reinforce social dominance. *Science* **357**:6347, 162-168. [[Crossref](#)]
26. Ran Zhang, Chuangang Liu, Yunzi Cao, Muhammad Jamal, Xi Chen, Jinfang Zheng, Liang Li, Jing You, Qi Zhu, Shiyong Liu, Jinxia Dai, Min Cui, Zhen F. Fu, Gang Cao. 2017. Rabies viruses leader RNA interacts with host Hsc70 and inhibits virus replication. *Oncotarget* **8**:27, 43822-43837. [[Crossref](#)]
27. Yuan-Rui Yang, Xiao-Yi Xiong, Juan Liu, Li-Rong Wu, Qi Zhong, Kai Zhou, Zhao-You Meng, Liang Liu, Fa-Xiang Wang, Qiu-Wen Gong, Mao-Fan Liao, Chun-Mei Duan, Jie Li, Mei-Hua Yang, Qin Zhang, Chang-Xiong Gong, Qing-Wu Yang. 2017. Mfsd2a (Major Facilitator Superfamily Domain Containing 2a) Attenuates Intracerebral Hemorrhage-Induced Blood-Brain Barrier Disruption by Inhibiting Vesicular Transcytosis. *Journal of the American Heart Association* **6**:7. . [[Crossref](#)]
28. J. B. Mason, B. L. Gurda, A. Van Wettere, J. B. Engiles, J. M. Wilson, D. W. Richardson. 2017. Delivery and evaluation of recombinant adeno-associated viral vectors in the equine distal extremity for the treatment of laminitis. *Equine Veterinary Journal* **49**:1, 79-86. [[Crossref](#)]
29. Elvir Becirovic, Sybille Böhm, Ong N. P. Nguyen, Lisa M. Riedmayr, Verena Hammelmann, Christian Schön, Elisabeth S. Butz, Christian Wahl-Schott, Martin Biel, Stylianos Michalakis. 2016. AAV Vectors for FRET-Based Analysis of Protein-Protein Interactions in Photoreceptor Outer Segments. *Frontiers in Neuroscience* **10**. . [[Crossref](#)]
30. Eva Auffenberg, Angela Jurik, Corinna Mattusch, Rainer Stoffel, Andreas Genewsky, Christian Namendorf, Roland M. Schmid, Gerhard Rammes, Martin Biel, Manfred Uhr, Sven Moosmang, Stylianos Michalakis, Carsten T. Wotjak, Christoph K. Thoeringer. 2016. Remote and reversible inhibition of neurons and circuits by small molecule induced potassium channel stabilization. *Scientific Reports* **6**:1. . [[Crossref](#)]
31. JUN ZHOU, PING MA, JUN LI, XIAONAN CUI, WEI SONG. 2016. Improvement of the cytotoxic T lymphocyte response against hepatocellular carcinoma by transduction of cancer cells with an adeno-associated virus carrying the interferon- γ gene. *Molecular Medicine Reports* **13**:4, 3197-3205. [[Crossref](#)]
32. Christian Schön, Sabrina Asteriti, Susanne Koch, Vithijanjali Sothilingam, Marina Garcia Garrido, Naoyuki Tanimoto, Jochen Herms, Mathias W. Seeliger, Lorenzo Cangiano, Martin Biel, Stylianos Michalakis. 2016. Loss of HCN1 enhances disease progression in mouse models of CNG channel-linked retinitis pigmentosa and achromatopsia. *Human Molecular Genetics* **25**:6, 1165-1175. [[Crossref](#)]
33. Salvatore Botta, Elena Marrocco, Nicola de Prisco, Fabiola Curion, Mario Renda, Martina Sofia, Mariangela Lupo, Annamaria Carissimo, Maria Laura Bacci, Carlo Gesualdo, Settimio Rossi, Francesca Simonelli, Enrico Maria Surace. 2016. Rhodopsin targeted transcriptional silencing by DNA-binding. *eLife* **5**. . [[Crossref](#)]
34. E Sugano, K Tabata, M Takahashi, F Nishiyama, H Shimizu, M Sato, M Tamai, H Tomita. 2016. Local and systemic responses following intravitreal injection of AAV2-encoded modified Volvox channelrhodopsin-1 in a genetically blind rat model. *Gene Therapy* **23**:2, 158-166. [[Crossref](#)]
35. Taro Tomono, Yukihiko Hirai, Hironori Okada, Kumi Adachi, Akiko Ishii, Takashi Shimada, Masafumi Onodera, Akira Tamaoka, Takashi Okada. 2016. Ultracentrifugation-free chromatography-mediated large-scale purification of recombinant adeno-associated virus serotype 1 (rAAV1). *Molecular Therapy - Methods & Clinical Development* **3**, 15058. [[Crossref](#)]
36. Pierre-Olivier Buclez, Gabriella Dias Florencio, Karima Relizani, Cyriaque Beley, Luis Garcia, Rachid Benchaouir. 2016. Rapid, scalable, and low-cost purification of recombinant adeno-associated virus produced by baculovirus expression vector system. *Molecular Therapy - Methods & Clinical Development* **3**, 16035. [[Crossref](#)]
37. Shuyong Zhu, Chengjiang Zhao, Yingying Wu, Qiaoqiao Yang, Aiyun Shao, Tiepeng Wang, Jianfu Wu, Yanqing Yin, Yandong Li, Jincan Hou, Xinhua Zhang, Guomin Zhou, Xiaosong Gu, Xiaomin Wang, Xosé R Bustelo, Jiawei Zhou. 2015. Identification of a Vav2-dependent mechanism for GDNF/Ret control of mesolimbic DAT trafficking. *Nature Neuroscience* **18**:8, 1084-1093. [[Crossref](#)]

38. Matthias Heindorf, Mazahir T. Hasan. 2015. Fluorescent Calcium Indicator Protein Expression in the Mouse Brain Using Recombinant Adeno-Associated Viruses. *Cold Spring Harbor Protocols* **2015**:7, pdb.prot087635. [[Crossref](#)]
39. Marianna Marino, Tatiana Stoilova, Carlotta Giorgi, Angela Bachi, Angela Cattaneo, Alberto Auricchio, Paolo Pinton, Ester Zito. 2015. SEPN1, an endoplasmic reticulum-localized selenoprotein linked to skeletal muscle pathology, counteracts hyperoxidation by means of redox-regulating SERCA2 pump activity. *Human Molecular Genetics* **24**:7, 1843-1855. [[Crossref](#)]
40. Yi Lin, Zhongjie Sun. 2015. In Vivo Pancreatic β -Cell-Specific Expression of Antiaging Gene Klotho : A Novel Approach for Preserving β -Cells in Type 2 Diabetes. *Diabetes* **64**:4, 1444-1458. [[Crossref](#)]
41. JUN ZHOU, PING MA, JUN LI, WEI SONG. 2015. Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells pulsed with recombinant adeno-associated virus carrying α -fetoprotein gene or cancer cell lysate. *Molecular Medicine Reports* **11**:4, 3174-3180. [[Crossref](#)]
42. Xianyou Wang, Feng Wang, Nana Li, Min Hu, Yun Chen, Mengqun Tan. 2015. The effects of endothelial progenitor cells on rat atherosclerosis. *Biotechnology and Applied Biochemistry* **62**:2, 186-192. [[Crossref](#)]
43. Xiaoxia Lu, Karen S. McCoy, Jiali Xu, Weikun Hu, Hebin Chen, Kun Jiang, Feng Han, Peng Chen, Yanli Wang. 2015. Galectin-9 ameliorates respiratory syncytial virus-induced pulmonary immunopathology through regulating the balance between Th17 and regulatory T cells. *Virus Research* **195**, 162-171. [[Crossref](#)]
44. Gabriella Dias Florencio, Guillaume Precigout, Cyriaque Beley, Pierre-Olivier Buclez, Luis Garcia, Rachid Benchaouir. 2015. Simple downstream process based on detergent treatment improves yield and in vivo transduction efficacy of adeno-associated virus vectors. *Molecular Therapy - Methods & Clinical Development* **2**, 15024. [[Crossref](#)]
45. Michihiro Mieda, Takeshi Sakurai. Pharmacogenetic Dissection of Neural Mechanisms Underlying the Regulation of Sleep-Wakefulness Using DREADDs 109-127. [[Crossref](#)]
46. Ling Hu, Wei Lan, Hao Guo, Guo-Dong Chai, Kun Huang, Ling Zhang, Ying Huang, Xue-Feng Chen, Lei Zhang, Ning-Ning Song, Ling Chen, Bing Lang, Yun Wang, Qing-Xiu Wang, Jin-Bao Zhang, Collin McCaig, Lin Xu, Yu-Qiang Ding. 2014. A mouse line for inducible and reversible silencing of specific neurons. *Molecular Brain* **7**:1. . [[Crossref](#)]
47. A Puppò, G Cesi, E Marrocco, P Piccolo, S Jacca, D M Shayakhmetov, R J Parks, B L Davidson, S Colloca, N Brunetti-Pierri, P Ng, G Donofrio, A Auricchio. 2014. Retinal transduction profiles by high-capacity viral vectors. *Gene Therapy* **21**:10, 855-865. [[Crossref](#)]
48. Christian Schmidt, Deon Bezuidenhout, Peter Zilla, Neil H Davies. 2014. A slow-release fibrin matrix increases adeno-associated virus transduction of wound repair cells in vivo. *Journal of Biomaterials Applications* **28**:9, 1408-1418. [[Crossref](#)]
49. Ivana Trapani, Pasqualina Colella, Andrea Sommella, Carolina Iodice, Giulia Cesi, Sonia de Simone, Elena Marrocco, Settimio Rossi, Massimo Giunti, Arpad Palfi, Gwyneth J Farrar, Roman Polishchuk, Alberto Auricchio. 2014. Effective delivery of large genes to the retina by dual AAV vectors. *EMBO Molecular Medicine* **6**:2, 194-211. [[Crossref](#)]
50. Doria Monica, Ferrara Antonella, Auricchio Alberto. 2013. AAV2/8 Vectors Purified from Culture Medium with a Simple and Rapid Protocol Transduce Murine Liver, Muscle, and Retina Efficiently. *Human Gene Therapy Methods* **24**:6, 392-398. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
51. Igor V. Ignatovich, Jacqueline A. Hobbs. 2013. Human parvovirus B19 infection leads to downregulation of thyroid, estrogen, and retinoid hormone receptor expression. *Virology* **446**:1-2, 173-179. [[Crossref](#)]
52. Kun Li, Tao Zhou, Lujian Liao, Zhongfei Yang, Catherine Wong, Fritz Henn, Roberto Malinow, John R. Yates, Hailan Hu. 2013. β CaMKII in Lateral Habenula Mediates Core Symptoms of Depression. *Science* **341**:6149, 1016-1020. [[Crossref](#)]
53. Pasqualina Colella, Andrea Sommella, Elena Marrocco, Umberto Di Vicino, Elena Polishchuk, Marina Garcia Garrido, Mathias W. Seeliger, Roman Polishchuk, Alberto Auricchio. 2013. Myosin7a Deficiency

Results in Reduced Retinal Activity Which Is Improved by Gene Therapy. *PLoS ONE* 8:8, e72027. [[Crossref](#)]

54. Jeffrey B. Mason, Brittney L. Gurda, Julie B. Engiles, Kurt D. Hankenson, James M. Wilson, Dean W. Richardson. 2013. Multiple Recombinant Adeno-Associated Viral Vector Serotypes Display Persistent In Vivo Gene Expression in Vector-Transduced Rat Stifle Joints. *Human Gene Therapy Methods* 24:3, 185-194. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
55. Agostina Puppo, Alexander Bello, Anna Manfredi, Giulia Cesi, Elena Marrocco, Michele Della Corte, Settimio Rossi, Massimo Giunti, Maria Laura Bacci, Francesca Simonelli, Enrico Maria Surace, Gary P. Kobinger, Alberto Auricchio. 2013. Recombinant Vectors Based on Porcine Adeno-Associated Viral Serotypes Transduce the Murine and Pig Retina. *PLoS ONE* 8:3, e59025. [[Crossref](#)]
56. Y Liu, K-I Joo, P Wang. 2013. Endocytic processing of adeno-associated virus type 8 vectors for transduction of target cells. *Gene Therapy* 20:3, 308-317. [[Crossref](#)]
57. DAN PENG, HOUJUAN ZUO, ZHENGXIANG LIU, JIN QIN, YUANLIN ZHOU, PENGCHENG LI, DAOWEN WANG, HESONG ZENG, XIN A. ZHANG. 2013. The tetraspanin CD151-ARSA mutant inhibits angiogenesis via the YRSL sequence. *Molecular Medicine Reports* 7:3, 836-842. [[Crossref](#)]
58. S. Koch, V. Sothilingam, M. Garcia Garrido, N. Tanimoto, E. Becirovic, F. Koch, C. Seide, S. C. Beck, M. W. Seeliger, M. Biel, R. Muhlfridel, S. Michalakakis. 2012. Gene therapy restores vision and delays degeneration in the CNGB1-/- mouse model of retinitis pigmentosa. *Human Molecular Genetics* 21:20, 4486-4496. [[Crossref](#)]
59. Chang-Xuan You, Min Shi, Yong Liu, Maohua Cao, Rongcheng Luo, Paul L. Hermonat. 2012. AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications. *OncoImmunology* 1:6, 847-855. [[Crossref](#)]
60. Jeffrey B. Mason, Luk H. Vandenberghe, Ru Xiao, James M. Wilson, Dean W. Richardson. 2012. Influence of serotype, cell type, tissue composition, and time after inoculation on gene expression in recombinant adeno-associated viral vector-transduced equine joint tissues. *American Journal of Veterinary Research* 73:8, 1178-1185. [[Crossref](#)]
61. Bingnan Li, Juan Zhang, Zhiyan Li, Mengqun Tan. 2012. Adeno-associated virus serotype 2 mediated transduction and coexpression of the human apoAI and SR-BI gene in HepG2 cells. *Molecular Biology Reports* 39:1, 25-32. [[Crossref](#)]
62. Stylianos Michalakakis, Regine Muhlfridel, Naoyuki Tanimoto, Vidhyasankar Krishnamoorthy, Susanne Koch, M. Dominik Fischer, Elvir Becirovic, Lin Bai, Gesine Huber, Susanne C. Beck, Edda Fahl, Hildegard Büning, Jennifer Schmidt, Xiangang Zong, Tim Gollisch, Martin Biel, Mathias W. Seeliger. Gene Therapy Restores Missing Cone-Mediated Vision in the CNGA3-/- Mouse Model of Achromatopsia 183-189. [[Crossref](#)]
63. Kleopatra Rapti, Roger J. Hajjar, Thomas Weber. Novel Approaches to Deliver Molecular Therapeutics in Cardiac Disease Using Adeno-Associated Virus Vectors 391-458. [[Crossref](#)]
64. Lijun Wang, Véronique Blouin, Nicole Brument, Mahajoub Bello-Roufai, Achille Francois. Production and Purification of Recombinant Adeno-Associated Vectors 361-404. [[Crossref](#)]
65. Zhujun Ao, Xiaoxia Wang, Alexander Bello, Kallesh Danappa Jayappa, Zhe Yu, Keith Fowke, Xinying He, Xi Chen, Junhua Li, Gary Kobinger, Xiaojian Yao. 2011. Characterization of Anti-HIV Activity Mediated by R88-APOBEC3G Mutant Fusion Proteins in CD4+ T cells, Peripheral Blood Mononuclear Cells, and Macrophages. *Human Gene Therapy* 22:10, 1225-1237. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
66. L. WANG, J.-P. LOUBOUTIN, P. BELL, J.A. GREIG, Y. LI, D. WU, J.M. WILSON. 2011. Muscle-directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors. *Journal of Thrombosis and Haemostasis* 9:10, 2009-2019. [[Crossref](#)]
67. Isao Murakami, Takamasa Takeuchi, Mayuyo Mori-Uchino, Seiichiro Mori, Takuma Fujii, Daisuke Aoki, Keiichi Nakagawa, Tadahito Kanda. 2011. An Adeno-Associated Virus Vector Efficiently and Specifically Transduces Mouse Skeletal Muscle. *Molecular Biotechnology* 49:1, 1-10. [[Crossref](#)]

68. C Mussolino, M della Corte, S Rossi, F Viola, U Di Vicino, E Marrocco, S Neglia, M Doria, F Testa, R Giovannoni, M Crasta, M Giunti, E Villani, M Lavitrano, M L Bacci, R Ratiglia, F Simonelli, A Auricchio, E M Surace. 2011. AAV-mediated photoreceptor transduction of the pig cone-enriched retina. *Gene Therapy* **18**:7, 637-645. [[Crossref](#)]
69. Jing Tian, Feng Wang, Jin-Feng Xue, Fei Zhao, Liu-Jiang Song, Meng-Qun Tan. 2011. Recombinant AAV2-mediated β -globin expression in human fetal hematopoietic cells from the aborted fetuses with β -thalassemia major. *International Journal of Hematology* **93**:6, 691-699. [[Crossref](#)]
70. Pasqualina Colella, Carolina Iodice, Umberto Di Vicino, Ida Annunziata, Enrico M. Surace, Alberto Auricchio. 2011. Non-erythropoietic erythropoietin derivatives protect from light-induced and genetic photoreceptor degeneration. *Human Molecular Genetics* **20**:11, 2251-2262. [[Crossref](#)]
71. Koh Sasaki, Mika Suzuki, Michihiro Mieda, Natsuko Tsujino, Bryan Roth, Takeshi Sakurai. 2011. Pharmacogenetic Modulation of Orexin Neurons Alters Sleep/Wakefulness States in Mice. *PLoS ONE* **6**:5, e20360. [[Crossref](#)]
72. Kye-Il Joo, Yun Fang, Yarong Liu, Liang Xiao, Zhen Gu, April Tai, Chi-Lin Lee, Yi Tang, Pin Wang. 2011. Enhanced Real-Time Monitoring of Adeno-Associated Virus Trafficking by Virus-Quantum Dot Conjugates. *ACS Nano* **5**:5, 3523-3535. [[Crossref](#)]
73. Wenqin Ma, Baozheng Li, Chen Ling, Giridhara R. Jayandharan, Arun Srivastava, Barry J. Byrne. 2011. A Simple Method to Increase the Transduction Efficiency of Single-Stranded Adeno-Associated Virus Vectors In Vitro and In Vivo. *Human Gene Therapy* **22**:5, 633-640. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
74. Carmine Spanpanato, Elvira De Leonibus, Paola Dama, Annagiusti Gargiulo, Alessandro Fraldi, Nicolina Cristina Sorrentino, Fabio Russo, Edoardo Nusco, Alberto Auricchio, Enrico M Surace, Andrea Ballabio. 2011. Efficacy of a Combined Intracerebral and Systemic Gene Delivery Approach for the Treatment of a Severe Lysosomal Storage Disorder. *Molecular Therapy* **19**:5, 860-869. [[Crossref](#)]
75. E Sugano, H Isago, Z Wang, N Murayama, M Tamai, H Tomita. 2011. Immune responses to adeno-associated virus type 2 encoding channelrhodopsin-2 in a genetically blind rat model for gene therapy. *Gene Therapy* **18**:3, 266-274. [[Crossref](#)]
76. Gabriella Cotugno, Patrizia Annunziata, Alessandra Tessitore, Thomas O'Malley, Anita Capalbo, Armida Faella, Rosa Bartolomeo, Patricia O'Donnell, Ping Wang, Fabio Russo, Meg M Sleeper, Van W Knox, Steven Fernandez, Leah Levanduski, John Hopwood, Elvira De Leonibus, Mark Haskins, Alberto Auricchio. 2011. Long-term Amelioration of Feline Mucopolysaccharidosis VI After AAV-mediated Liver Gene Transfer. *Molecular Therapy* **19**:3, 461-469. [[Crossref](#)]
77. Gabriella Cotugno, Michela Aurilio, Patrizia Annunziata, Anita Capalbo, Armida Faella, Valentina Rinaldi, Caterina Strisciuglio, Maurizio Di Tommaso, Luigi Aloj, Alberto Auricchio. 2011. Noninvasive Repetitive Imaging of Somatostatin Receptor 2 Gene Transfer with Positron Emission Tomography. *Human Gene Therapy* **22**:2, 189-196. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)] [[Supplementary Material](#)]
78. Chen Ling, Yuan Lu, Jasmine K. Kalsi, Giridhara R. Jayandharan, Baozheng Li, Wenqin Ma, Binbin Cheng, Samantha W.Y. Gee, Katherine E. McGoogan, Lakshmanan Govindasamy, Li Zhong, Mavis Agbandje-McKenna, Arun Srivastava. 2010. Human Hepatocyte Growth Factor Receptor Is a Cellular Coreceptor for Adeno-Associated Virus Serotype 3. *Human Gene Therapy* **21**:12, 1741-1747. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
79. Stylianos Michalakis, Regine Mühlfriedel, Naoyuki Tanimoto, Vidhyasankar Krishnamoorthy, Susanne Koch, M Dominik Fischer, Elvir Becirovic, Lin Bai, Gesine Huber, Susanne C Beck, Edda Fahl, Hildegard Büning, François Paquet-Durand, Xiangang Zong, Tim Gollisch, Martin Biel, Mathias W Seeliger. 2010. Restoration of Cone Vision in the CNGA3^{-/-} Mouse Model of Congenital Complete Lack of Cone Photoreceptor Function. *Molecular Therapy* **18**:12, 2057-2063. [[Crossref](#)]

80. Shuwen Cao, Shaji Theodore, David G Standaert. 2010. Fcγ receptors are required for NF-κB signaling, microglial activation and dopaminergic neurodegeneration in an AAV-synuclein mouse model of Parkinson's disease. *Molecular Neurodegeneration* 5:1. . [[Crossref](#)]
81. Yong Cao, Daxiong Zeng, Qingfeng Song, Chao Cao, Min Xie, Xiansheng Liu, Shengdao Xiong, Yongjian Xu, Weining Xiong. 2010. The effects of antisense interleukin-4 gene transferred by recombinant adeno-associated virus vector on the airway remodeling in allergic rats. *Journal of Asthma* 47:9, 951-958. [[Crossref](#)]
82. Martin Lock, Mauricio Alvira, Luk H. Vandenberghe, Arabinda Samanta, Jaan Toelen, Zeger Debyser, James M. Wilson. 2010. Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale. *Human Gene Therapy* 21:10, 1259-1271. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
83. Axel Doenecke, Alexander Krömer, Marcus N. Scherer, Hans-Jürgen Schlitt, Edward K. Geissler. 2010. AAV plasmid DNA simplifies liver-directed in vivo gene therapy: comparison of expression levels after plasmid DNA-, adeno-associated virus- and adenovirus-mediated liver transfection. *The Journal of Gene Medicine* 12:10, 810-817. [[Crossref](#)]
84. Hongfei Ge, Yumei Xiong, Bryan Lemon, Ki Jeong Lee, Jay Tang, Ping Wang, Jennifer Weiszmann, Nessa Hawkins, John Laudemann, Xiaoshan Min, David Penny, Tom Wolfe, Qiang Liu, Richard Zhang, Weh-Chen Yeh, Wenyan Shen, Richard Lindberg, Zhulun Wang, Jackie Sheng, Yang Li. 2010. Generation of Novel Long-Acting Globular Adiponectin Molecules. *Journal of Molecular Biology* 399:1, 113-119. [[Crossref](#)]
85. Giridhara R. Jayandharan, Li Zhong, Brandon K. Sack, Angela E. Rivers, Mengxin Li, Baozheng Li, Roland W. Herzog, Arun Srivastava. 2010. Optimized Adeno-Associated Virus (AAV)-Protein Phosphatase-5 Helper Viruses for Efficient Liver Transduction by Single-Stranded AAV Vectors: Therapeutic Expression of Factor IX at Reduced Vector Doses. *Human Gene Therapy* 21:3, 271-283. [[Abstract](#)] [[Full Text](#)] [[PDF](#)] [[PDF Plus](#)]
86. Hiroshi Tomita, Eriko Sugano, Hitomi Isago, Teru Hiroi, Zhuo Wang, Emi Ohta, Makoto Tamai. 2010. Channelrhodopsin-2 gene transduced into retinal ganglion cells restores functional vision in genetically blind rats. *Experimental Eye Research* 90:3, 429-436. [[Crossref](#)]
87. Feng Wang, Jinfeng Xue, Danjun Wang, Xianyou Wang, Shukun Lu, Mengqun Tan. 2010. Treatment of Atherosclerosis by Transplantation of Bone Endothelial Progenitor Cells Over-Expressed Paraoxonase-1 Gene by Recombinant Adeno-Associated Virus in Rat. *Biological & Pharmaceutical Bulletin* 33:11, 1806-1813. [[Crossref](#)]
88. Daxiong ZENG, Yong CAO, Qingfeng SONG, Chao CAO, Xiansheng LIU, Yongjian XU, Weining XIONG. 2010. Effects of antisense interleukin-5 gene transferred by recombinant adeno-associated virus to allergic rats. *Respirology* 15:1, 132-140. [[Crossref](#)]
89. Giou-Teng Yiang, Horng-Jyh Harn, Yung-Luen Yu, Sheng-Chuan Hu, Yu-Ting Hung, Chia-Jung Hsieh, Shinn-Zong Lin, Chyou-Wei Wei. 2009. Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice. *Journal of Biomedical Science* 16:1. . [[Crossref](#)]
90. Shyam Daya, Nenita Cortez, Kenneth I. Berns. 2009. Adeno-Associated Virus Site-Specific Integration Is Mediated by Proteins of the Nonhomologous End-Joining Pathway. *Journal of Virology* 83:22, 11655-11664. [[Crossref](#)]
91. Gong-Bo Li, Guang-Xiu Lu. 2009. Gene Delivery Efficiency in Bone Marrow-derived Dendritic Cells: Comparison of Four Methods and Optimization for Lentivirus Transduction. *Molecular Biotechnology* 43:3, 250-256. [[Crossref](#)]
92. A Bello, K Tran, A Chand, M Doria, M Allocca, M Hildinger, D Beniac, C Kranendonk, A Auricchio, G P Kobinger. 2009. Isolation and evaluation of novel adeno-associated virus sequences from porcine tissues. *Gene Therapy* 16:11, 1320-1328. [[Crossref](#)]

93. Richard H Smith, Justin R Levy, Robert M Kotin. 2009. A Simplified Baculovirus-AAV Expression Vector System Coupled With One-step Affinity Purification Yields High-titer rAAV Stocks From Insect Cells. *Molecular Therapy* 17:11, 1888-1896. [[Crossref](#)]
94. Jennifer Wang, Mazahir T. Hasan, H. Sebastian Seung. 2009. Laser-evoked synaptic transmission in cultured hippocampal neurons expressing channelrhodopsin-2 delivered by adeno-associated virus. *Journal of Neuroscience Methods* 183:2, 165-175. [[Crossref](#)]
95. Houjuan Zuo, Zhengxiang Liu, Xiaochun Liu, Jun Yang, Tao Liu, Sha Wen, Xin A. Zhang, Katherine Cianflone, Daowen Wang. 2009. CD151 Gene Delivery after Myocardial Infarction Promotes Functional Neovascularization and Activates FAK Signaling. *Molecular Medicine* 15:9-10, 307-315. [[Crossref](#)]
96. Jiangao Zhu, Xiaopei Huang, Yiping Yang. 2009. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. *Journal of Clinical Investigation* 119:8, 2388-2398. [[Crossref](#)]
97. Mayuyo Mori-Uchino, Takamasa Takeuchi, Isao Murakami, Tetsu Yano, Toshiharu Yasugi, Yuji Taketani, Keiichi Nakagawa, Tadahito Kanda. 2009. Enhanced transgene expression in the mouse skeletal muscle infected by the adeno-associated viral vector with the human elongation factor 1 α promoter and a human chromatin insulator. *The Journal of Gene Medicine* 11:7, 598-604. [[Crossref](#)]
98. Barbara Di Benedetto, Benedikt Wefers, Wolfgang Wurst, Ralf Kühn. 2009. Local Knockdown of ERK2 in the Adult Mouse Brain Via Adeno-Associated Virus-Mediated RNA Interference. *Molecular Biotechnology* 41:3, 263-269. [[Crossref](#)]
99. M S Oh, S J Hong, Y Huh, K-S Kim. 2009. Expression of transgenes in midbrain dopamine neurons using the tyrosine hydroxylase promoter. *Gene Therapy* 16:3, 437-440. [[Crossref](#)]
100. L H Vandenbergh, J M Wilson, G Gao. 2009. Tailoring the AAV vector capsid for gene therapy. *Gene Therapy* 16:3, 311-319. [[Crossref](#)]
101. Shaji Theodore, Shuwen Cao, Pamela J. McLean, David G. Standaert. 2008. Targeted Overexpression of Human α -Synuclein Triggers Microglial Activation and an Adaptive Immune Response in a Mouse Model of Parkinson Disease. *Journal of Neuropathology & Experimental Neurology* 67:12, 1149-1158. [[Crossref](#)]
102. Rosemary H. Milton, Rosella Abeti, Stefania Averaimo, Silvia DeBiasi, Laura Vitellaro, Lele Jiang, Paul M. G. Curmi, Samuel N. Breit, Michael R. Duchen, Michele Mazzanti. 2008. CLIC1 Function Is Required for β -Amyloid-Induced Generation of Reactive Oxygen Species by Microglia. *The Journal of Neuroscience* 28:45, 11488-11499. [[Crossref](#)]
103. Li Zhong, Baozheng Li, Giridhararao Jayandharan, Cathryn S. Mah, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Roland W. Herzog, Kirsten A. Weigel-Van Aken, Jacqueline A. Hobbs, Sergei Zolotukhin, Nicholas Muzyczka, Arun Srivastava. 2008. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. *Virology* 381:2, 194-202. [[Crossref](#)]
104. G R Jayandharan, L Zhong, B Li, B Kachniarz, A Srivastava. 2008. Strategies for improving the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo. *Gene Therapy* 15:18, 1287-1293. [[Crossref](#)]
105. Hongwei Li, Yongxin Gao, Yanfei Qi, Michael J. Katovich, Nan Jiang, Leah N. Braseth, Deborah A. Scheuer, Peng Shi, Colin Sumners. 2008. Macrophage migration inhibitory factor in hypothalamic paraventricular nucleus neurons decreases blood pressure in spontaneously hypertensive rats. *The FASEB Journal* 22:9, 3175-3185. [[Crossref](#)]
106. Ming Li, Jide Wang, Samuel S. M. Ng, Chu-Yan Chan, Amy C. Chen, Hong Ping Xia, David T. Yew, Benjamin C. Y. Wong, Zhu Chen, Hsiang-Fu Kung, Marie Chia-Mi Lin. 2008. The four-and-a-half-LIM protein 2 (FHL2) is overexpressed in gliomas and associated with oncogenic activities. *Glia* 56:12, 1328-1338. [[Crossref](#)]

107. Jiang-tao YAN, Tao WANG, Juan LI, Xiao XIAO, Dao-wen WANG. 2008. Recombinant adeno-associated virus-mediated human kallikrein gene therapy prevents high-salt diet-induced hypertension without effect on basal blood pressure 1. *Acta Pharmacologica Sinica* **29**:7, 808-814. [[Crossref](#)]
108. A. Negrete, R. M. Kotin. 2008. Strategies for manufacturing recombinant adeno-associated virus vectors for gene therapy applications exploiting baculovirus technology. *Briefings in Functional Genomics and Proteomics* **7**:4, 303-311. [[Crossref](#)]
109. Li Zhong, Baozheng Li, Cathryn S. Mah, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Mario Cooper, Roland W. Herzog, Irene Zolotukhin, Kenneth H. Warrington, Kirsten A. Weigel-Van Aken, Jacqueline A. Hobbs, Sergei Zolotukhin, Nicholas Muzyczka, Arun Srivastava. 2008. Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses. *Proceedings of the National Academy of Sciences* **105**:22, 7827-7832. [[Crossref](#)]
110. Michela Alessandra Denti, Tania Incitti, Olga Sthandier, Carmine Nicoletti, Fernanda Gabriella De Angelis, Emanuele Rizzuto, Alberto Auricchio, Antonio Musarò, Irene Bozzoni. 2008. Long-Term Benefit of Adeno-Associated Virus/Antisense-Mediated Exon Skipping in Dystrophic Mice. *Human Gene Therapy* **19**:6, 601-608. [[Abstract](#)] [[PDF](#)] [[PDF Plus](#)]
111. S Cecchini, A Negrete, R M Kotin. 2008. Toward exascale production of recombinant adeno-associated virus for gene transfer applications. *Gene Therapy* **15**:11, 823-830. [[Crossref](#)]
112. Zhi Li, Hong Yao, Yan Ma, Qingming Dong, Yangchao Chen, Ying Peng, Bo-jian Zheng, Jian-dong Huang, Chu-yan Chan, Marie C. Lin, Joseph J Sung, Kwok Yun Yuen, Hsiang-fu Kung, Ming-Liang He. 2008. Inhibition of HBV gene expression and replication by stably expressed interferon- α 1 via adeno-associated viral vectors. *The Journal of Gene Medicine* **10**:6, 619-627. [[Crossref](#)]
113. Seiichiro Mori, Takamasa Takeuchi, Tadahito Kanda. 2008. Antibody-dependent enhancement of adeno-associated virus infection of human monocytic cell lines. *Virology* **375**:1, 141-147. [[Crossref](#)]
114. Mariacarmela Allocca, Monica Doria, Marco Petrillo, Pasqualina Colella, Maria Garcia-Hoyos, Daniel Gibbs, So Ra Kim, Albert Maguire, Tonia S. Rex, Umberto Di Vicino, Luisa Cutillo, Janet R. Sparrow, David S. Williams, Jean Bennett, Alberto Auricchio. 2008. Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. *Journal of Clinical Investigation* **118**:5, 1955-1964. [[Crossref](#)]
115. Ling Tu, Xizhen Xu, Huaibing Wan, Changqing Zhou, Juanjuan Deng, Gang Xu, Xiao Xiao, Yipu Chen, Matthew L. Edin, James W. Voltz, Darryl C. Zeldin, Dao Wen Wang. 2008. Delivery of Recombinant Adeno-Associated Virus-Mediated Human Tissue Kallikrein for Therapy of Chronic Renal Failure in Rats. *Human Gene Therapy* **19**:4, 318-330. [[Abstract](#)] [[PDF](#)] [[PDF Plus](#)]
116. Shellie M. Callahan, Piyanuch Wonganan, Linda J. Obenauer-Kutner, Suganto Sutjipto, Joseph D. Dekker, Maria A. Croyle. 2008. Controlled inactivation of recombinant viruses with vitamin B2. *Journal of Virological Methods* **148**:1-2, 132-145. [[Crossref](#)]
117. M Natkunarajah, P Trittibach, J McIntosh, Y Duran, S E Barker, A J Smith, A C Nathwani, R R Ali. 2008. Assessment of ocular transduction using single-stranded and self-complementary recombinant adeno-associated virus serotype 2/8. *Gene Therapy* **15**:6, 463-467. [[Crossref](#)]
118. Ke Song, Nianjing Rao, Meiling Chen, Yingguang Cao. 2008. Construction of adeno-associated virus system for human bone morphogenetic protein 7 gene. *Journal of Huazhong University of Science and Technology [Medical Sciences]* **28**:1, 17-21. [[Crossref](#)]
119. Rory J. McCrimmon, Margaret Shaw, Xiaoning Fan, Haiying Cheng, Yuyan Ding, Monica C. Vella, Ligang Zhou, Ewan C. McNay, Robert S. Sherwin. 2008. Key Role for AMP-Activated Protein Kinase in the Ventromedial Hypothalamus in Regulating Counterregulatory Hormone Responses to Acute Hypoglycemia. *Diabetes* **57**:2, 444-450. [[Crossref](#)]
120. Richard H. Smith, Linda Yang, Robert M. Kotin. Chromatography-Based Purification of Adeno-Associated Virus 37-54. [[Crossref](#)]

121. Marc G. Aucoin, Michel Perrier, Amine A. Kamen. 2008. Critical assessment of current adeno-associated viral vector production and quantification methods. *Biotechnology Advances* **26**:1, 73-88. [[Crossref](#)]
122. Ayse Ulusoy, Tomas Bjorklund, Stephan Hermening, Deniz Kirik. 2008. In vivo gene delivery for development of mammalian models for Parkinson's disease. *Experimental Neurology* **209**:1, 89-100. [[Crossref](#)]
123. H Petry, A Brooks, A Orme, P Wang, P Liu, J Xie, P Kretschmer, H S Qian, T W Hermiston, R N Harkins. 2008. Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice. *Gene Therapy* **15**:1, 54-60. [[Crossref](#)]
124. Alessandra Tessitore, Armida Faella, Thomas O'Malley, Gabriella Cotugno, Monica Doria, Tetsuo Kunieda, Giuseppe Matarese, Mark Haskins, Alberto Auricchio. 2008. Biochemical, Pathological, and Skeletal Improvement of Mucopolysaccharidosis VI After Gene Transfer to Liver but Not to Muscle. *Molecular Therapy* **16**:1, 30-37. [[Crossref](#)]
125. Tao WANG, Ling-bo HOU, Zhen-jun LIU, Yan WANG, Chun-lian CHEN, Xiao XIAO, Dao-wen WANG. 2007. Intramuscular delivery of rAAV-mediated kallikrein gene reduces hypertension and prevents cardiovascular injuries in model rats. *Acta Pharmacologica Sinica* **28**:12, 1898-1906. [[Crossref](#)]
126. Alessandro Fraldi, Kim Hemsley, Allison Crawley, Alessia Lombardi, Adeline Lau, Leanne Sutherland, Alberto Auricchio, Andrea Ballabio, John J. Hopwood. 2007. Functional correction of CNS lesions in an MPS-IIIa mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. *Human Molecular Genetics* **16**:22, 2693-2702. [[Crossref](#)]
127. Xu-guang Li, Jiang-tao Yan, Xi-zheng Xu, Jia-ning Wang, Li-ming Cheng, Tao Wang, Ping Zuo, Dao-wen Wang. 2007. Recombinant adeno-associated virus-mediated delivery of antisense angiotensin II receptor 1 gene attenuates hypertension development. *Acta Pharmacologica Sinica* **28**:11, 1737-1745. [[Crossref](#)]
128. Mariacarmela Allocca, Claudio Mussolino, Maria Garcia-Hoyos, Daniela Sanges, Carolina Iodice, Marco Petrillo, Luk H. Vandenberghe, James M. Wilson, Valeria Marigo, Enrico M. Surace, Alberto Auricchio. 2007. Novel Adeno-Associated Virus Serotypes Efficiently Transduce Murine Photoreceptors. *Journal of Virology* **81**:20, 11372-11380. [[Crossref](#)]
129. Mahendran Mahadevan, Yong Liu, Changxuan You, Rongcheng Luo, Hong You, Jawahar L. Mehta, Paul L. Hermonat. 2007. Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus. *Cancer Immunology, Immunotherapy* **56**:10, 1615-1624. [[Crossref](#)]
130. Markus Hildinger, Lucia Baldi, Matthieu Stettler, Florian M. Wurm. 2007. High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cells. *Biotechnology Letters* **29**:11, 1713-1721. [[Crossref](#)]
131. K Yuasa, M Yoshimura, N Urasawa, S Ohshima, J M Howell, A Nakamura, T Hijikata, Y Miyagoe-Suzuki, S Takeda. 2007. Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products. *Gene Therapy* **14**:17, 1249-1260. [[Crossref](#)]
132. Joshua N. Leonard, Peter Ferstl, Antonio Delgado, David V. Schaffer. 2007. Enhanced preparation of adeno-associated viral vectors by using high hydrostatic pressure to selectively inactivate helper adenovirus. *Biotechnology and Bioengineering* **97**:5, 1170-1179. [[Crossref](#)]
133. Mirosław Kozłowski, Darin E. Olson, Janet Rubin, Dorota Lyszkowicz, Adam Campbell, Peter M. Thulé. 2007. Adeno-associated viral delivery of a metabolically regulated insulin transgene to hepatocytes. *Molecular and Cellular Endocrinology* **273**:1-2, 6-15. [[Crossref](#)]
134. Li Zhong, Weihong Zhao, Jianqing Wu, Baozheng Li, Sergei Zolotukhin, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Arun Srivastava. 2007. A Dual Role of EGFR Protein Tyrosine Kinase Signaling in Ubiquitination of AAV2 Capsids and Viral Second-strand DNA Synthesis. *Molecular Therapy* **15**:7, 1323-1330. [[Crossref](#)]

135. Paul Szymanski, Peter J Kretschmer, Maxine Bauzon, Fang Jin, Hu Sheng Qian, Gabor M Rubanyi, Richard N Harkins, Terry W Hermiston. 2007. Development and Validation of a Robust and Versatile One-plasmid Regulated Gene Expression System. *Molecular Therapy* **15**:7, 1340-1347. [[Crossref](#)]
136. Mary O'Reilly, Arpad Palfi, Naomi Chadderton, Sophia Millington-Ward, Marius Ader, Thérèse Cronin, Thérèse Tuohy, Alberto Auricchio, Markus Hildinger, Amanda Tivnan, Niamh McNally, Marian M. Humphries, Anna-Sophia Kiang, Pete Humphries, Paul F. Kenna, G. Jane Farrar. 2007. RNA Interference-Mediated Suppression and Replacement of Human Rhodopsin In Vivo. *The American Journal of Human Genetics* **81**:1, 127-135. [[Crossref](#)]
137. Chien-Ming Hu, Heng-Huei Lin, Ming-Tsai Chiang, Pi-Fei Chang, Lee-Young Chau. 2007. Systemic Expression of Heme Oxygenase-1 Ameliorates Type 1 Diabetes in NOD Mice. *Diabetes* **56**:5, 1240-1247. [[Crossref](#)]
138. Tse-Wei Yue, Wei-Che Chien, S.-Ja Tseng, Shiue-Cheng Tang. 2007. EDC/NHS-mediated heparinization of small intestinal submucosa for recombinant adeno-associated virus serotype 2 binding and transduction. *Biomaterials* **28**:14, 2350-2357. [[Crossref](#)]
139. Li Zhong, Weihong Zhao, Jianqing Wu, Baozheng Li, Sergei Zolotukhin, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Arun Srivastava. 2007. A Dual Role of EGFR Protein Tyrosine Kinase Signaling in Ubiquitination of AAV2 Capsids and Viral Second-strand DNA Synthesis. *Molecular Therapy* . [[Crossref](#)]
140. Alessandro Fraldi, Alessandra Biffi, Alessia Lombardi, Ilaria Visigalli, Stefano Pepe, Carmine Settembre, Edoardo Nusco, Alberto Auricchio, Luigi Naldini, Andrea Ballabio, Maria Pia Cosma. 2007. SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies. *Biochemical Journal* **403**:2, 305-312. [[Crossref](#)]
141. James T. Koerber, Jae-Hyung Jang, Julie H. Yu, Ravi S. Kane, David V. Schaffer. 2007. Engineering Adeno-Associated Virus for One-Step Purification via Immobilized Metal Affinity Chromatography. *Human Gene Therapy* **18**:4, 367-378. [[Abstract](#)] [[PDF](#)] [[PDF Plus](#)]
142. Min Wang, Brian P. Ramos, Constantinos D. Paspalas, Yousheng Shu, Arthur Simen, Alvaro Duque, Susheel Vijayraghavan, Avis Brennan, Anne Dudley, Eric Nou, James A. Mazer, David A. McCormick, Amy F.T. Arnsten. 2007. α 2A-Adrenoceptors Strengthen Working Memory Networks by Inhibiting cAMP-HCN Channel Signaling in Prefrontal Cortex. *Cell* **129**:2, 397-410. [[Crossref](#)]
143. Keyun Qing, Yanyun Chen. 2007. Central CART gene delivery by recombinant AAV vector attenuates body weight gain in diet-induced-obese rats. *Regulatory Peptides* **140**:1-2, 21-26. [[Crossref](#)]
144. Jean-Marc Taymans, Luk H. Vandenberghe, Chris Van Den Haute, Irina Thiry, Christophe M. Deroose, Luc Mortelmans, James M. Wilson, Zeger Debyser, Veerle Baekelandt. 2007. Comparative Analysis of Adeno-Associated Viral Vector Serotypes 1, 2, 5, 7, And 8 in Mouse Brain. *Human Gene Therapy* **18**:3, 195-206. [[Abstract](#)] [[PDF](#)] [[PDF Plus](#)]
145. Jianqing Wu, Weihong Zhao, Li Zhong, Zongchao Han, Baozheng Li, Wenqin Ma, Kirsten A. Weigel-Kelley, Kenneth H. Warrington , Jr., Arun Srivastava. 2007. Self-Complementary Recombinant Adeno-Associated Viral Vectors: Packaging Capacity And The Role of Rep Proteins in Vector Purity. *Human Gene Therapy* **18**:2, 171-182. [[Abstract](#)] [[PDF](#)] [[PDF Plus](#)]
146. Gabriella Cotugno, Pietro Formisano, Ferdinando Giacco, Pasqualina Colella, Francesco Beguinot, Alberto Auricchio. 2007. AP20187-Mediated Activation of A Chimeric Insulin Receptor Results in Insulin-Like Actions in Skeletal Muscle And Liver of Diabetic Mice. *Human Gene Therapy* **18**:2, 106-117. [[Abstract](#)] [[PDF](#)] [[PDF Plus](#)]
147. Parminder S. Chahal, Marc G. Aucoin, Amine Kamen. 2007. Primary recovery and chromatographic purification of adeno-associated virus type 2 produced by baculovirus/insect cell system. *Journal of Virological Methods* **139**:1, 61-70. [[Crossref](#)]

148. S G Sumner-Jones, L A Davies, A Varathalingam, D R Gill, S C Hyde. 2006. Long-term persistence of gene expression from adeno-associated virus serotype 5 in the mouse airways. *Gene Therapy* **13**:24, 1703-1713. [[Crossref](#)]
149. Michael P Boyle, Raymond A Enke, Jeffrey B Reynolds, Peter J Mogayzel, William B Guggino, Pamela L Zeitlin. 2006. Membrane-associated heparan sulfate is not required for rAAV-2 infection of human respiratory epithelia. *Virology Journal* **3**:1. . [[Crossref](#)]
150. Robert E. MacLaren, Prateek K. Buch, Alexander J. Smith, Kamaljit S. Balaggan, Angus MacNeil, Jeremy S. Taylor, Neville N. Osborne, Robin R. Ali. 2006. CNTF gene transfer protects ganglion cells in rat retinae undergoing focal injury and branch vessel occlusion. *Experimental Eye Research* **83**:5, 1118-1127. [[Crossref](#)]
151. Yong Liu, Dayuan Li, Jiawei Chen, Jin Xie, Sarmistha Bandyopadhyay, Dazhi Zhang, Aravind R. Nemarkommula, Hongmei Liu, Jawahar L. Mehta, Paul L. Hermonat. 2006. Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. *Atherosclerosis* **188**:1, 19-27. [[Crossref](#)]
152. Zhijian Wu, Aravind Asokan, R. Jude Samulski. 2006. Adeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy. *Molecular Therapy* **14**:3, 316-327. [[Crossref](#)]
153. Zhenzhong Zheng, Zhengxiang Liu. 2006. CD151 Gene Delivery Activates PI3K/Akt Pathway and Promotes Neovascularization after Myocardial Infarction in Rats. *Molecular Medicine* **12**:9-10, 214-220. [[Crossref](#)]
154. M. Begoña Cachón-González, Susan Z. Wang, Andrew Lynch, Robin Ziegler, Seng H. Cheng, Timothy M. Cox. 2006. Effective gene therapy in an authentic model of Tay-Sachs-related diseases. *Proceedings of the National Academy of Sciences* **103**:27, 10373-10378. [[Crossref](#)]
155. Michela Alessandra Denti, Alessandro Rosa, Giuseppe D'Antona, Olga Sthandier, Fernanda Gabriella De Angelis, Carmine Nicoletti, Mariacarmela Allocca, Orietta Pansarasa, Valeria Parente, Antonio Musaro, Alberto Auricchio, Roberto Bottinelli, Irene Bozzoni. 2006. Chimeric Adeno-Associated Virus/Antisense U1 Small Nuclear RNA Effectively Rescues Dystrophin Synthesis and Muscle Function by Local Treatment of mdx Mice. *Human Gene Therapy*, ahead of print060801084750006. [[Crossref](#)]
156. Dayuan Li, Yong Liu, Jiawei Chen, Neelima Velchala, Fariba Amani, Aravind Nemarkommula, Kui Chen, Hassan Rayaz, Dazhi Zhang, Hongmei Liu, Anjan K. Sinha, Francesco Romeo, Paul L. Hermonat, Jawahar L. Mehta. 2006. Suppression of atherogenesis by delivery of TGF β 1 ACT using adeno-associated virus type 2 in LDLR knockout mice. *Biochemical and Biophysical Research Communications* **344**:3, 701-707. [[Crossref](#)]
157. Michela Alessandra Denti, Alessandro Rosa, Giuseppe D'Antona, Olga Sthandier, Fernanda Gabriella De Angelis, Carmine Nicoletti, Mariacarmela Allocca, Orietta Pansarasa, Valeria Parente, Antonio Musarò, Alberto Auricchio, Roberto Bottinelli, Dr. Irene Bozzoni. 2006. Chimeric Adeno-Associated Virus/Antisense U1 Small Nuclear RNA Effectively Rescues Dystrophin Synthesis and Muscle Function by Local Treatment of mdx Mice. *Human Gene Therapy* **17**:5, 565-574. [[Abstract](#)] [[PDF](#)] [[PDF Plus](#)]
158. Xiang-Ping Li, Christine Y.S. Li, Xiaohua Li, Yanqing Ding, Lally L.Y. Chan, Pai-Hao Yang, Gang Li, Xiong Liu, Jennifer S. Lin, Jide Wang, Mingliang He, Hsiang-fu Kung, Marie C. Lin, Ying Peng. 2006. Inhibition of human nasopharyngeal carcinoma growth and metastasis in mice by adenovirus-associated virus-mediated expression of human endostatin. *Molecular Cancer Therapeutics* **5**:5, 1290-1298. [[Crossref](#)]
159. Michela Alessandra Denti, Alessandro Rosa, Giuseppe D'Antona, Olga Sthandier, Fernanda Gabriella De Angelis, Carmine Nicoletti, Mariacarmela Allocca, Orietta Pansarasa, Valeria Parente, Antonio Musarò, Alberto Auricchio, Roberto Bottinelli, Irene Bozzoni. 2006. Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. *Proceedings of the National Academy of Sciences* **103**:10, 3758-3763. [[Crossref](#)]

160. Yong CAO, Wei-ning XIONG, Yong-jian XU, Zhen-xiang ZHANG, Bao-an GAO, Chun-ling DU, Jun-yu LU, Tao YE. 2006. Recombinant adeno-associated virus-mediated inhibiting of interleukin-4 expression in rat model of asthma. *Chinese Medical Journal* **119**:3, 223-225. [[Crossref](#)]
161. Manuel AFV Gonçalves. 2005. Adeno-associated virus: from defective virus to effective vector. *Virology Journal* **2**:1. . [[Crossref](#)]
162. Mihaela Sin, Paul D. Walker, Mohamad Bouhamdan, John P. Quinn, Michael J. Bannon. 2005. Preferential expression of an AAV-2 construct in NOS-positive interneurons following intrastriatal injection. *Molecular Brain Research* **141**:1, 74-82. [[Crossref](#)]
163. Hong T. Le, Qian-Chun Yu, James M. Wilson, Maria A. Croyle. 2005. Utility of PEGylated recombinant adeno-associated viruses for gene transfer. *Journal of Controlled Release* **108**:1, 161-177. [[Crossref](#)]
164. Enrico Maria Surace, Luciano Domenici, Katia Cortese, Gabriella Cotugno, Umberto Di Vicino, Consuelo Venturi, Alessandro Cellerino, Valeria Marigo, Carlo Tacchetti, Andrea Ballabio, Alberto Auricchio. 2005. Amelioration of both Functional and Morphological Abnormalities in the Retina of a Mouse Model of Ocular Albinism Following AAV-Mediated Gene Transfer. *Molecular Therapy* **12**:4, 652-658. [[Crossref](#)]
165. E Burova, E Ioffe. 2005. Chromatographic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications. *Gene Therapy* **12**:S1, S5-S17. [[Crossref](#)]
166. A M Duffy, A M O'Doherty, T O'Brien, P M Strappe. 2005. Purification of adenovirus and adeno-associated virus: comparison of novel membrane-based technology to conventional techniques. *Gene Therapy* **12**:S1, S62-S72. [[Crossref](#)]
167. Fan ZHANG, Chun Lian CHEN, Jia Qing QIAN, Jiang Tao YAN, Katherine CIANFLONE, Xiao XIAO, Dao Wen WANG. 2005. Long-term modifications of blood pressure in normotensive and spontaneously hypertensive rats by gene delivery of rAAV-mediated cytochrome P450 arachidonic acid hydroxylase. *Cell Research* **15**:9, 717-724. [[Crossref](#)]
168. Rong Fang Lan, Zheng Xiang Liu, Xiao Chun Liu, Yu E. Song, Dao Wen Wang. 2005. CD151 Promotes Neovascularization and Improves Blood Perfusion in a Rat Hind-Limb Ischemia Model. *Journal of Endovascular Therapy* **12**:4, 469-478. [[Crossref](#)]
169. C. Y. Wang, H. Y. Guo, T. M. Lim, Y. K. Ng, H. P. Neo, P. Y. K. Hwang, W.-C. Yee, S. Wang. 2005. Improved neuronal transgene expression from an AAV-2 vector with a hybrid CMV enhancer/PDGF- β promoter. *The Journal of Gene Medicine* **7**:7, 945-955. [[Crossref](#)]
170. Chamsy Sarkis, Jacques Mallet. Gene therapy 329-346. [[Crossref](#)]
171. Shiue-Cheng Tang, Athanassios Sambanis, Eric Sibley. 2005. Proteasome modulating agents induce rAAV2-mediated transgene expression in human intestinal epithelial cells. *Biochemical and Biophysical Research Communications* **331**:4, 1392-1400. [[Crossref](#)]
172. Fernando Ezquer, Marco Tulio Núñez, Yedy Israel. 2005. Antisense gene delivered by an adenoassociated viral vector inhibits iron uptake in human intestinal cells: Potential application in hemochromatosis. *Biochemical Pharmacology* **69**:11, 1559-1566. [[Crossref](#)]
173. Dr. S. Zolotukhin. 2005. Production of Recombinant Adeno-Associated Virus Vectors. *Human Gene Therapy* **16**:5, 551-557. [[Abstract](#)] [[PDF](#)] [[PDF Plus](#)]
174. Corinna Lebherz, Albert M. Maguire, Alberto Auricchio, Waixing Tang, Tomas S. Aleman, Zhangyong Wei, Rebecca Grant, Artur V. Cideciyan, Samuel G. Jacobson, James M. Wilson, Jean Bennett. 2005. Nonhuman Primate Models for Diabetic Ocular Neovascularization Using AAV2-Mediated Overexpression of Vascular Endothelial Growth Factor. *Diabetes* **54**:4, 1141-1149. [[Crossref](#)]
175. Xin Wei, Chunxia Zhao, Jiangang Jiang, Juan Li, Xiao Xiao, Dr. Dao Wen Wang. 2005. Adrenomedullin Gene Delivery Alleviates Hypertension and Its Secondary Injuries of Cardiovascular System. *Human Gene Therapy* **16**:3, 372-380. [[Abstract](#)] [[PDF](#)] [[PDF Plus](#)]
176. Yong Liu, Maurizio Chiriva-Internati, Changxuan You, Rongcheng Luo, Hong You, C Krishna Prasad, Fabio Grizzi, Everardo Cobos, V Suzanne Klimberg, Helen Kay, Jawahar L Mehta, Paul L Hermonat.

2005. Use and specificity of breast cancer antigen/milk protein BA46 for generating anti-self-cytotoxic T lymphocytes by recombinant adeno-associated virus-based gene loading of dendritic cells. *Cancer Gene Therapy* 12:3, 304-312. [[Crossref](#)]
177. Qing Xie, Joan Hare, Joy Turnigan, Michael S Chapman. 2004. Large-scale production, purification and crystallization of wild-type adeno-associated virus-2. *Journal of Virological Methods* 122:1, 17-27. [[Crossref](#)]
178. Gabriella Cotugno, Roy Pollock, Pietro Formisano, Katja Linher, Francesco Beguinot, Dr. Alberto Auricchio. 2004. Pharmacological Regulation of the Insulin Receptor Signaling Pathway Mimics Insulin Action in Cells Transduced with Viral Vectors. *Human Gene Therapy* 15:11, 1101-1108. [[Abstract](#)] [[PDF](#)] [[PDF Plus](#)]
179. Nalini Agrawal, Hong You, Yong Liu, Maurizio Chiriva-Internati, John Bremner, Tarun Garg, Fabio Grizzi, C. Krishna Prasad, Jawahar L. Mehta, Paul L. Hermonat. 2004. Generation of Recombinant Skin in Vitro by Adeno-Associated Virus Type 2 Vector Transduction. *Tissue Engineering* 10:11-12, 1707-1715. [[Abstract](#)] [[PDF](#)] [[PDF Plus](#)]
180. Andrew M. Davidoff, Catherine Y.C. Ng, Susan Sleep, John Gray, Selina Azam, Yuan Zhao, Jenny H. McIntosh, Morteza Karimipoor, Amit C. Nathwani. 2004. Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. *Journal of Virological Methods* 121:2, 209-215. [[Crossref](#)]
181. Simone Berlinghoff, Marlon R. Veldwijk, Stephanie Laufs, Hans-Peter Maser, Anna Jauch, Frederik Wenz, W. Jens Zeller, Stefan Fruehauf. 2004. Susceptibility of mesothelioma cell lines to adeno-associated virus 2 vector-based suicide gene therapy. *Lung Cancer* 46:2, 179-186. [[Crossref](#)]
182. Li Zhong, Linyuan Chen, Yanjun Li, Keyun Qing, Kirsten A. Weigel-Kelley, Rebecca J. Chan, Mervin C. Yoder, Arun Srivastava. 2004. Self-complementary Adeno-associated Virus 2 (AAV)-T Cell Protein Tyrosine Phosphatase Vectors as Helper Viruses to Improve Transduction Efficiency of Conventional Single-Stranded AAV Vectors in Vitro and in Vivo. *Molecular Therapy* 10:5, 950-957. [[Crossref](#)]
183. Tonia S. Rex, Mariacarmela Allocca, Luciano Domenici, Enrico M. Surace, Albert M. Maguire, Arkady Lyubarsky, Alessandro Cellerino, Jean Bennett, Alberto Auricchio. 2004. Systemic but not intraocular Epo Gene Transfer Protects the Retina from Light-and Genetic-Induced Degeneration. *Molecular Therapy* 10:5, 855-861. [[Crossref](#)]
184. T Wang, H Li, C Zhao, C Chen, J Li, J Chao, L Chao, X Xiao, D W Wang. 2004. Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries. *Gene Therapy* 11:17, 1342-1350. [[Crossref](#)]
185. Marlon R Veldwijk, Simone Berlinghoff, Stephanie Laufs, Ulrich R Hengge, W Jens Zeller, Frederik Wenz, Stefan Fruehauf. 2004. Suicide gene therapy of sarcoma cell lines using recombinant adeno-associated virus 2 vectors. *Cancer Gene Therapy* 11:8, 577-584. [[Crossref](#)]
186. Francesco Vetrini, Alberto Auricchio, Jinyan Du, Barbara Angeletti, David E. Fisher, Andrea Ballabio, Valeria Marigo. 2004. The Microphthalmia Transcription Factor (Mitf) Controls Expression of the Ocular Albinism Type 1 Gene: Link between Melanin Synthesis and Melanosome Biogenesis. *Molecular and Cellular Biology* 24:15, 6550-6559. [[Crossref](#)]
187. Piotr Hadaczek, Hanna Mirek, John Bringas, Janet Cunningham, Krys Bankiewicz. 2004. Basic Fibroblast Growth Factor Enhances Transduction, Distribution, and Axonal Transport of Adeno-Associated Virus Type 2 Vector in Rat Brain. *Human Gene Therapy* 15:5, 469-479. [[Abstract](#)] [[PDF](#)] [[PDF Plus](#)]
188. Paul J Kostenuik, Brad Bolon, Sean Morony, Mark Daris, Zhaopo Geng, Christopher Carter, Jackie Sheng. 2004. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. *Bone* 34:4, 656-664. [[Crossref](#)]
189. Markus Hildinger, Alberto Auricchio. 2004. Advances in AAV-mediated gene transfer for the treatment of inherited disorders. *European Journal of Human Genetics* 12:4, 263-271. [[Crossref](#)]

190. Yoshitaka Iwanaga, Masahiko Hoshijima, Yusu Gu, Mitsuo Iwatate, Thomas Dieterle, Yasuhiro Ikeda, Moto-o Date, Jacqueline Chrast, Masunori Matsuzaki, Kirk L. Peterson, Kenneth R. Chien, John Ross. 2004. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. *Journal of Clinical Investigation* **113**:5, 727-736. [[Crossref](#)]
191. Danny Chu, Christopher C Sullivan, Lingling Du, Augustine J Cho, Masakuni Kido, Paul L Wolf, Matthew D Weitzman, Stuart W Jamieson, Patricia A Thistlethwaite. 2004. A new animal model for pulmonary hypertension based on the overexpression of a single gene, angiotensin-1. *The Annals of Thoracic Surgery* **77**:2, 449-456. [[Crossref](#)]
192. Wu Xiao, Chun Zhang, Preeti Yadava, Jeffrey Hughes. Nucleic Acid Cellular Delivery 81-94. [[Crossref](#)]
193. A. Doenecke, M. N. Scherer, E. Frank, A. Krömer, C. Graeb, H. J. Schlitt, E. K. Geissler. Erster Nachweis einer in-vivo Langzeitexpression löslicher Spender-MHC Klasse I-Antigene mittels rekombinanten adeno-assoziierten Virus (rAAV) im Rattenmodell: essentieller Schritt auf dem Weg zur Toleranzinduktion in der Organtransplantation 359-361. [[Crossref](#)]
194. Karsten Velde, Michael W. Ross, James A. Orsini, Eric J. Parente, Brian Foley, Dean W. Richardson, Richard R. Miselis. 2004. Tracing Axons of Peripheral Nerves in Rats: A Potential Technique to Study the Equine Recurrent Laryngeal Nerve. *Journal of Investigative Surgery* **17**:3, 151-162. [[Crossref](#)]
195. Barrie Carter, Haim Burstein, Richard Peluso. Adeno-associated Virus and AAV Vectors for Gene Delivery 71-101. [[Crossref](#)]
196. Richard H. Smith, Chuantian Ding, Robert M. Kotin. 2003. Serum-free production and column purification of adeno-associated virus type 5. *Journal of Virological Methods* **114**:2, 115-124. [[Crossref](#)]
197. Hong Wang, Li Lin, Jiangang Jiang, Yan Wang, Zai Ying Lu, J. Alyce Bradbury, Fred Bjørn Lih, Dao Wen Wang, Darryl C. Zeldin. 2003. Up-Regulation of Endothelial Nitric-Oxide Synthase by Endothelium-Derived Hyperpolarizing Factor Involves Mitogen-Activated Protein Kinase and Protein Kinase C Signaling Pathways. *Journal of Pharmacology and Experimental Therapeutics* **307**:2, 753-764. [[Crossref](#)]
198. M Iwatate, Y Gu, T Dieterle, Y Iwanaga, K L Peterson, M Hoshijima, K R Chien, J Ross. 2003. In vivo high-efficiency transcortical gene delivery and Cre-LoxP gene switching in the adult mouse heart. *Gene Therapy* **10**:21, 1814-1820. [[Crossref](#)]
199. Danny Chu, Christopher C Sullivan, Matthew D Weitzman, Lingling Du, Paul L Wolf, Stuart W Jamieson, Patricia A Thistlethwaite. 2003. Direct comparison of efficiency and stability of gene transfer into the mammalian heart using adeno-associated virus versus adenovirus vectors. *The Journal of Thoracic and Cardiovascular Surgery* **126**:3, 671-679. [[Crossref](#)]
200. Keith D.K Luk, Yan Chen, Kenneth M.C Cheung, Hsiang-fu Kung, William W Lu, John C.Y Leong. 2003. Adeno-associated virus-mediated bone morphogenetic protein-4 gene therapy for in vivo bone formation. *Biochemical and Biophysical Research Communications* **308**:3, 636-645. [[Crossref](#)]
201. Alexander J Smith, Frank C Schlichtenbrede, Marion Tschernutter, James W Bainbridge, Adrian J Thrasher, Robin R Ali. 2003. AAV-Mediated gene transfer slows photoreceptor loss in the RCS rat model of retinitis pigmentosa. *Molecular Therapy* **8**:2, 188-195. [[Crossref](#)]
202. Y Chen, K D K Luk, K M C Cheung, R Xu, M C Lin, W W Lu, J C Y Leong, H-F Kung. 2003. Gene therapy for new bone formation using adeno-associated viral bone morphogenetic protein-2 vectors. *Gene Therapy* **10**:16, 1345-1353. [[Crossref](#)]
203. Enrico M. Surace, Alberto Auricchio, Samuel J. Reich, Tonia Rex, Ernest Glover, Stacey Pineles, Waixing Tang, Erin O'Connor, Arkady Lyubarsky, Andrey Savchenko, Edward N. Pugh, Albert M. Maguire, James M. Wilson, Jean Bennett. 2003. Delivery of Adeno-Associated Virus Vectors to the Fetal Retina: Impact of Viral Capsid Proteins on Retinal Neuronal Progenitor Transduction. *Journal of Virology* **77**:14, 7957-7963. [[Crossref](#)]

204. Andrew D. Smith, Roy F. Collaco, James P. Trempe. 2003. Enhancement of Recombinant Adeno-Associated Virus Type 2-Mediated Transgene Expression in a Lung Epithelial Cell Line by Inhibition of the Epidermal Growth Factor Receptor. *Journal of Virology* 77:11, 6394-6404. [[Crossref](#)]
205. Shiue-Cheng Tang, Athanassios Sambanis. 2003. Development of genetically engineered human intestinal cells for regulated insulin secretion using rAAV-mediated gene transfer. *Biochemical and Biophysical Research Communications* 303:2, 645-652. [[Crossref](#)]
206. Hideo Yasukawa, Toshitaka Yajima, Hervé Duplain, Mitsuo Iwatate, Masakuni Kido, Masahiko Hoshijima, Matthew D. Weitzman, Tomoyuki Nakamura, Sarah Woodard, Dingding Xiong, Akihiko Yoshimura, Kenneth R. Chien, Kirk U. Knowlton. 2003. The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. *Journal of Clinical Investigation* 111:4, 469-478. [[Crossref](#)]
207. Alberto Auricchio, Paul D. Acton, Markus Hildinger, Jean-Pierre Louboutin, Karl Plössl, Erin O'Connor, Hank F. Kung, James M. Wilson. 2003. In Vivo Quantitative Noninvasive Imaging of Gene Transfer by Single-Photon Emission Computerized Tomography. *Human Gene Therapy* 14:3, 255-261. [[Abstract](#)] [[PDF](#)] [[PDF Plus](#)]
208. Tatiana Zavorotinskaya, Adrian Tomkinson, John E. Murphy. 2003. Treatment of experimental asthma by long-term gene therapy directed against IL-4 and IL-13. *Molecular Therapy* 7:2, 155-162. [[Crossref](#)]
209. S.J. Reich, A. Auricchio, M. Hildinger, E. Glover, A.M. Maguire, J.M. Wilson, J. Bennett. 2003. Efficient Trans-Splicing in the Retina Expands the Utility of Adeno-Associated Virus as a Vector for Gene Therapy. *Human Gene Therapy* 14:1, 37-44. [[Abstract](#)] [[PDF](#)] [[PDF Plus](#)]
210. L. Parsons, J. Watson, Patricia Connolly, Michael J. Heller, Jeffrey Bonadio, Peter C. Johnson, Jack M. Loomis, Britton Chance, Kyung A. Kang, Edgar Garcia-Rill, Gregor Wolbring, Rodolfo R. Llinás, Valeri A. Makarov, Miguel A. L. Nicolelis, Mandayam A. Srinivasan, Abraham Phillip Lee, Larry Cauller, Andy Penz, Alan T. Pope, Olafur S. Poisson, U. Calgary, R. Golledge. Improving Human Health and Physical Capabilities 179-273. [[Crossref](#)]
211. Nicole Brument, Robert Morenweiser, Véronique Blouin, Estelle Toubanc, Isabelle Raimbaud, Yan Chérel, Sébastien Folliot, Florence Gaden, Pierre Boulanger, Gabrielle Kroner-Lux, Philippe Moullier, Fabienne Rolling, Anna Salvetti. 2002. A Versatile and Scalable Two-Step Ion-Exchange Chromatography Process for the Purification of Recombinant Adeno-associated Virus Serotypes-2 and -5. *Molecular Therapy* 6:5, 678-686. [[Crossref](#)]
212. Alberto Auricchio, Kathryn C. Behling, Albert M. Maguire, Erin E. O'Connor, Jean Bennett, James M. Wilson, Michael J. Tolentino. 2002. Inhibition of Retinal Neovascularization by Intraocular Viral-Mediated Delivery of Anti-angiogenic Agents. *Molecular Therapy* 6:4, 490-494. [[Crossref](#)]
213. Richard O. Snyder, Terence R. Flotte. 2002. Production of clinical-grade recombinant adeno-associated virus vectors. *Current Opinion in Biotechnology* 13:5, 418-423. [[Crossref](#)]
214. Takashi Okada, Tatsuya Nomoto, Kuniko Shimazaki, Wang Lijun, Yanyan Lu, Takashi Matsushita, Hiroaki Mizukami, Masashi Urabe, Yutaka Hanazono, Akihiro Kume, Shin-ichi Muramatsu, Imaharu Nakano, Keiya Ozawa. 2002. Adeno-associated virus vectors for gene transfer to the brain. *Methods* 28:2, 237-247. [[Crossref](#)]
215. . Gene Therapy: Historical Overview and Public Oversight 26-55. [[Crossref](#)]
216. Tippi C. MacKenzie, Gary P. Kobinger, Neeltje A. Kootstra, Antoneta Radu, Miguel Sena-Estevés, Sarah Bouchard, James M. Wilson, Inder M. Verma, Alan W. Flake. 2002. Efficient Transduction of Liver and Muscle after in Utero Injection of Lentiviral Vectors with Different Pseudotypes. *Molecular Therapy* 6:3, 349-358. [[Crossref](#)]
217. Alberto Auricchio, Erin O'Connor, Daniel Weiner, Guang-Ping Gao, Markus Hildinger, Lili Wang, Roberto Calcedo, James M. Wilson. 2002. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. *Journal of Clinical Investigation* 110:4, 499-504. [[Crossref](#)]

218. Marlon R Veldwijk, Julian Topaly, Stephanie Laufs, Ulrich R Hengge, Frederik Wenz, W.Jens Zeller, Stefan Fruehauf. 2002. Development and Optimization of a Real-Time Quantitative PCR-Based Method for the Titration of AAV-2 Vector Stocks. *Molecular Therapy* 6:2, 272-278. [[Crossref](#)]
219. Alberto Auricchio, Victor M Rivera, Tim Clackson, Erin E O'Connor, Albert M Maguire, Michael J Tolentino, Jean Bennett, James M Wilson. 2002. Pharmacological Regulation of Protein Expression from Adeno-Associated Viral Vectors in the Eye. *Molecular Therapy* 6:2, 238-242. [[Crossref](#)]
220. Masahiko Hoshijima, Yasuhiro Ikeda, Yoshitaka Iwanaga, Susumu Minamisawa, Moto-o Date, Yusu Gu, Mitsuo Iwatate, Manxiang Li, Lili Wang, James M. Wilson, Yibin Wang, John Ross, Kenneth R. Chien. 2002. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. *Nature Medicine* 8:8, 864-871. [[Crossref](#)]
221. JEFFREY BONADIO, MICHAEL L. CUNNINGHAM. 2002. Genetic Approaches to Craniofacial Tissue Repair. *Annals of the New York Academy of Sciences* 961:1, 48-57. [[Crossref](#)]
222. Mihail Y. Mastakov, Kristin Baer, Robert M. Kotin, Matthew J. During. 2002. Recombinant Adeno-associated Virus Serotypes 2- and 5-Mediated Gene Transfer in the Mammalian Brain: Quantitative Analysis of Heparin Co-infusion. *Molecular Therapy* 5:4, 371-380. [[Crossref](#)]
223. Joseph E. Rabinowitz, Fabienne Rolling, Chengwen Li, Hervé Conrath, Weidong Xiao, Xiao Xiao, R. Jude Samulski. 2002. Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity. *Journal of Virology* 76:2, 791-801. [[Crossref](#)]
224. Yong Liu, Maurizio Chiriva-Internati, Fabio Grizzi, Emanuela Salati, Juan J Roman, Seah Lim, Paul L Hermonat. 2001. Rapid induction of cytotoxic T-cell response against cervical cancer cells by human papillomavirus type 16 E6 antigen gene delivery into human dendritic cells by an adeno-associated virus vector. *Cancer Gene Therapy* 8:12, 948-957. [[Crossref](#)]
225. Alberto Auricchio, Erin O'Connor, Markus Hildinger, James M. Wilson. 2001. A Single-Step Affinity Column for Purification of Serotype-5 Based Adeno-associated Viral Vectors. *Molecular Therapy* 4:4, 372-374. [[Crossref](#)]
226. Markus Hildinger, Alberto Auricchio, Guangping Gao, Lili Wang, Narendra Chirmule, James M. Wilson. 2001. Hybrid Vectors Based on Adeno-Associated Virus Serotypes 2 and 5 for Muscle-Directed Gene Transfer. *Journal of Virology* 75:13, 6199-6203. [[Crossref](#)]